| Date and Time: | | | Monday, June 12, 2023 3:00 pm British Summer Time/10:00 am Eastern Time | | |||
| Virtual Meeting Site: | | | www.meetnow.global/ | | |||
| Shareholders Eligible to Attend: | | | Shareholders of record at the close of The Nasdaq Stock Market LLC exchange on April A member who is entitled to attend and vote is entitled to appoint another person as a proxy to exercise all or any of his/her rights to attend, speak and vote at the meeting on his/her behalf in respect of the ordinary shares with nominal value £1 per share (each, an “Ordinary Share”) held by him/her. For information on attending and voting at the meeting and appointing a proxy, see our Frequently Asked Questions about the AGM. | | |||
| Number of Votes Outstanding: | | | The Company only has one class of voting share, being the Ordinary Shares. At April | |
| | No. | | | Proposed Resolution | | | Board Voting Recommendations | | | ||
| | 1 | | | Ordinary Resolution: To elect, by separate resolutions, each of the following nine (9) directors for a term expiring at the AGM to be held in a. Francesco Bianchi b. Stacy Enxing Seng c. William Kozy d. Daniel Moore e. Dr. Sharon O’Kane f. Andrea Saia g. Todd Schermerhorn h. Brooke Story i. Peter Wilver | | | For (in respect of each nominee) |
| | |||||||||||
| | 2 | | | Ordinary Resolution: To approve, on an advisory basis, the Company’s compensation of its named executive officers (“US Say-on-Pay”). | | | For | | | ||
| | 3 | | | Ordinary Resolution: To ratify the appointment of PricewaterhouseCoopers LLP, a Delaware limited liability partnership (“PwC-US”), as the Company’s independent registered public accounting | | | For | | | ||
| | 4 | | | Ordinary Resolution: To approve the Amended and Restated LivaNova PLC 2022 Incentive Award | | | For | | | ||
| | 5 | | | Ordinary Resolution: To generally and unconditionally authorize the directors, for the purposes of section 551 of the Companies Act 2006 (the “Companies Act”) to exercise all powers of the Company to allot shares in the Company and to grant rights to subscribe for, or to convert any security into, shares in the Company up to an aggregate nominal amount of provided that: (A) (unless previously revoked, varied or renewed by the Company) this authority will expire at the end of the next annual general meeting of the Company or, if earlier, the close of business on the date that is fifteen (15) months after the date on which this resolution is passed, save that the directors may, before this authority expires, make offers or agreements which would or might require shares in the Company to be allotted, or rights to subscribe for, or convert securities into, shares to be granted, after its expiry and the directors may allot shares or grant rights to subscribe for, or convert securities into, shares pursuant to such offers or agreements as if this authority had not expired, and (B) this authority replaces all subsisting authorities previously granted to the directors for the purposes of section 551 of the Companies Act which, to the extent unused at the date of this resolution, are revoked with immediate effect without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made under such authorities. | | | For | |
| | No. | | | Proposed Resolution | | | Board Voting Recommendations | | | ||
| | 6 | | | Special Resolution: Subject to the passing of resolution 5 and in accordance with sections 570 and 573 of the Companies Act, to empower the directors generally to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the authority conferred by resolution 5, and/or to sell cash up to an aggregate nominal amount of |
provided that: (A) (unless previously revoked, varied or renewed by the Company) this power will expire at the end of the next annual general meeting of the Company or, if earlier, the close of business on the date that is fifteen (15) months after the date on which this resolution is passed, save that the directors may, before this power expires, make offers or agreements which would or might require equity securities to be allotted and/or treasury shares to be sold after its expiry and the directors may allot equity securities and/or sell treasury shares pursuant to such offers or agreement as if this power had not expired; and (B) this power replaces (except for any power conferred by resolution 5) all subsisting powers previously granted to the directors for the purposes of section 570 of the Companies Act which, to the extent unused at the date of this resolution, are revoked with immediate effect, without prejudice to any allotment of equity securities already made, offered or agreed to be made under such powers. | | | | | ||||||||
| | 7 | | | Ordinary Resolution: To approve, on an advisory basis, the United Kingdom (“UK”) directors’ remuneration report in the form set out in the Company’s UK annual report (the “UK Annual Report”) for the period ended December 31, | | | For | | | ||
| | 8 | | | Ordinary Resolution: To | | | For | | | ||
| | 9 | | | Ordinary Resolution | |||||||
| | For | | | ||||||||
| | | | Ordinary Resolution: To authorize the directors and/or the Audit and Compliance Committee to determine the remuneration of the Company’s UK statutory auditor. | | | For | | |
| | | Internet www.envisionreports.com/LIVN and use the 15 Digit Control Number in the shaded area of your proxy Card or Notice Card or as directed by your broker, as the case may be | | |
| | | Telephone Call the number on your proxy card | | |
| | | By mail Sign, date and return your proxy card in the enclosed envelope | |
| | | Attending virtually at www.meetnow.global/ | |
| | | | | 1 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | 62 | | | |
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| ||||||||
| | | | | | |||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | | ||
| | | | | | |
| ☑ Annual Board and Committee Self-Evaluations. The Board and each of its committees conducts a self-evaluation of its performance on an annual basis. ☑ Regular Review of Key Governance Documents. Review of committee charters and Corporate Governance Guidelines at least annually or on a more frequent basis, as needed. ☑ Regular Executive Sessions. All regularly scheduled Board and committee meetings provide an opportunity for the directors to meet without management present. ☑ Robust Code of Ethics and Business Conduct. Provides the foundation for how directors and employees represent the Company. | | | ☑ Annual Election of Directors. All directors stand for election on an annual basis. ☑ Majority Voting in Uncontested Director Elections. All director nominees must receive an affirmative vote of the majority of votes cast in an uncontested election. ☑ Independent Lead Director. We believe that our Lead Director provides strong independent oversight of management and enhances our Board leadership structure. ☑ Financial Literacy for Audit Committee. Three Audit Committee members that are director nominees are “audit committee financial experts” under the rules of the SEC. | |
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors | | | | | 3 | | | | | | 7 | | | | | | 0 | | | | | | 0 | | |
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | |
African American or Black | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | | | |
Alaskan Native or Native American | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | | | |
Asian | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | | | |
Native Hawaiian or Pacific Islander | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | | | |
White | | | | | 3 | | | | | | 6 | | | | | | 0 | | | | | | | | |
Latinx | | | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | | | |
Two or More Races or Ethnicities | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | | | |
LGBTQ+ | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | | | |
Did Not Disclose | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | | | |
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||||||||
Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
Directors | | | | | 4 | | | | | | 5 | | | | | | 0 | | | | | | 0 | | |
Part II: Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | |
African American or Black | | | | | 1* | | | | | | 0 | | | | | | 0 | | | | | | | | |
White | | | | | 3 | | | | | | 4 | | | | | | 0 | | | | | | | | |
Hispanic or Latinx | | | | | 0 | | | | | | 1** | | | | | | 0 | | | | | | | | |
Name | | Occupation | | Independent | | Age | | Director Since | | Audit Committee | | Compensation Committee | | Nominating Committee | | | Occupation | | Independent | | Age | | Director Since | | Audit Committee | | Compensation Committee | | Nominating and Corporate Governance Committee | | ||||||||||||||||||||
William Kozy (Chair) | | Former EVP and COO, Becton, Dickinson and Company | | Yes | | | | 70 | | | 2018 | | | | | | | | ||||||||||||||||||||||||||||||||
William Kozy (Interim CEO and Chair of the Board) | | Interim CEO, LivaNova Former EVP and COO, Becton, Dickinson and Company | | No | | | | 71 | | | 2018 | | | | | | | | ||||||||||||||||||||||||||||||||
Francesco Bianchi | | Chair, Seven Capital Partners S.r.l. | | Yes | | | | 65 | | | 2015 | | X | | X | | | | | Chair, Seven Capital Partners S.r.l. | | Yes | | | | 66 | | | 2015 | | X | | X | | | | ||||||||||||||
Stacy Enxing Seng | | Operating Partner, Lightstone Ventures | | Yes | | | | 57 | | | 2019 | | | | Chair | | | | | Operating Partner, Lightstone Ventures | | Yes | | | | 58 | | | 2019 | | | | Chair | | | | ||||||||||||||
Damien McDonald | | CEO, LivaNova | | No | | | | 57 | | | 2017 | | | | | | | | ||||||||||||||||||||||||||||||||
Daniel Moore | | Private investor | | Yes | | | | 61 | | | 2015 | | | | | | X | | | Private Investor | | Yes | | | | 62 | | | 2015 | | | | | | X | |
Name | | Occupation | | Independent | | Age | | Director Since | | Audit Committee | | Compensation Committee | | Nominating Committee | | | Occupation | | Independent | | Age | | Director Since | | Audit Committee | | Compensation Committee | | Nominating and Corporate Governance Committee | | ||||||||||||||||||||
Dr. Sharon O’Kane | | Non-executive director of the Health Products Regulatory Authority Board in Ireland; Entrepreneur in Residence, University College Dublin | | Yes | | | | 54 | | | 2015 | | | | | | Chair | | ||||||||||||||||||||||||||||||||
Dr. Sharon O’Kane (Lead Director) | | Non-executive director of the Health Products Regulatory Authority Board in Ireland; Entrepreneur in Residence, University College Dublin | | Yes | | | | 55 | | | 2015 | | | | | | Chair | | ||||||||||||||||||||||||||||||||
Andrea Saia | | Former Global Head of Vision Care, Alcon Division, Novartis AG | | Yes | | | | 64 | | | 2016 | | X | | | | X | | | Former Global Head of Vision Care, Alcon Division, Novartis AG | | Yes | | | | 65 | | | 2016 | | X | | | | X | | ||||||||||||||
Todd Schermerhorn | | Former SVP and Chief Financial Officer, C.R. Bard, Inc. | | Yes | | | | 61 | | | 2020 | | Chair | | | | | | | Former SVP and Chief Financial Officer, C.R. Bard, Inc. | | Yes | | | | 62 | | | 2020 | | Chair | | | | | | ||||||||||||||
Brooke Story | | Worldwide President of Integrated Diagnostic Solutions, Becton, Dickinson and Company | | Yes | | | | 51 | | | 2022 | | | | | | X | | ||||||||||||||||||||||||||||||||
Peter Wilver | | Former EVP and Chief Administrative Officer, Thermo Fisher Scientific Inc. | | Yes | | | | 62 | | | 2022 | | | | | | | | | Former EVP and Chief Administrative Officer, Thermo Fisher Scientific Inc. | | Yes | | | | 63 | | | 2022 | | X | | X | | | |
| Board Independence | | | • • Our Interim CEO and Chair of the Board is our only management director | • We hold regular executive sessions of independent directors | | ||
| Board Composition | | | • | • Recent Board refreshment with the addition of two new independent directors in 2022 | | ||
| Board Committees | | | • We have three committees: ◦ Audit and Compliance ◦ Compensation ◦ Nominating and Corporate Governance • All of the members of our committees are independent • We conduct annual Board and | | |||
| Leadership Structure | | | • Our Chair • Our | | |||
| Risk Oversight | | | • Our Board is responsible for risk oversight and has designated committees to have particular oversight of certain key risks including cybersecurity, compensation, succession and | | |||
| Director Stock Ownership | | | • Directors are required to hold meaningful equity ownership positions in the Company • A • | | |||
| Accountability to Shareholders | | | • We use majority voting in director elections • All of our directors are elected each year • We do not have a shareholder rights (“poison pill”) plan • Since the past proxy season, we have engaged with the majority of our top • • We retain the ability to clawback awards in specified situations through our | |
| | Under its charter, the Audit and Compliance Committee’s key responsibilities include: • Reviewing our accounting, financial reporting and disclosure processes and the audit of our consolidated financial • Reviewing our internal controls with management and the independent auditors; • • • Reviewing the process by which cybersecurity risks are managed; • Reviewing the qualifications and independence of our independent auditors engaged for the purpose of auditing our consolidated financial statements and issuing an audit report for inclusion in appropriate regulatory filings; and • Selecting, subject to required shareholder approvals, our independent auditors and evaluating their The Audit and Compliance Committee meets at least quarterly with management, including the Head of Internal Audit, the Chief Legal Officer, the Chief Accounting Officer, the Chief Financial Officer, the Chief Ethics and Integrity |
Officer | | | Todd Schermerhorn (Chair) Francesco Bianchi Peter Wilver Andrea Saia Ten meetings in 2022 The Audit and Compliance Committee | | |
| | Under its charter, the Compensation Committee is responsible for, among other things, the following: • • Determining and approving the compensation of all other executive officers; • Reviewing, verifying and certifying the achievement of any performance goals for long-term and short-term incentive plans; • Reviewing and approving incentive compensation plans and equity-based plans and, where appropriate or required, recommending such plans for shareholder approval; • Administering (including adopting, amending and terminating) incentive compensation and equity-based plans; • Reviewing and discussing with management the Compensation Discussion and Analysis to be included in appropriate regulatory filings and determining whether to recommend to the Board that the Compensation Discussion and Analysis be included in such filings; • Submitting to the Board and shareholders for • Reviewing director compensation and benefits at least annually; • Producing the Compensation Committee Report for inclusion in the Company’s annual proxy statement or annual report on Form 10-K, as well as the Remuneration Report • Approving employment agreements and severance arrangements or plans for executive Determining stock ownership guidelines / requirements for directors and executive officers and monitoring compliance with such guidelines / requirements; and • Reviewing our incentive compensation arrangements to | | | | Members: Stacy Enxing Seng (Chair) Francesco Bianchi Peter Wilver The Compensation Committee Report is on page | | |
| | Under the terms of its charter, the Nominating and Corporate Governance Committee is responsible for, among other things: • • Administering the process for identifying candidates for membership on the Board, including the inclusion of at least one woman and at least one member of an underrepresented minority in every slate of potential nominees, developing criteria for Board and committee memberships and recommending and recruiting director nominees; • Evaluating the independence and other standards applicable to service on the Board and its committees, including whether each Audit and Compliance Committee member is financially literate and whether the Audit and Compliance Committee has at least one “audit committee financial expert;” • Evaluating and recommending changes, as appropriate, to Board and committee size, composition and chair and committee structure; and administering the process for regular Board and committee self-evaluations; • • Overseeing our corporate governance practices and procedures and reviewing such procedures at least annually; • Reviewing annually and recommending, for Board approval, a succession plan in respect of the CEO and reviewing periodically, succession planning for the Company’s • | | | Members: Dr. Sharon O’Kane (Chair) Daniel Moore Andrea Saia Brooke Story Four meetings in | | |
Directors | | | Nasdaq “Independent Director” | | | Nasdaq Independence for Compensation Committee Purposes | | | “Non-Employee Director” | | | Audit Committee Financial Expert | | ||||||||||||
Francesco Bianchi | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
Stacy Enxing Seng | | | | | X | | | | | | X | | | | | | X | | | | | | | | |
William Kozy | | | | | |||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | |||||
Daniel Moore | | | | | X | | | | | | X | | | | | | X | | | | | | | | |
Dr. Sharon O’Kane | |||||||||||||||||||||||||
| | | | X | | | | | | X | | | | | | X | | | | | | | | | |
Andrea Saia | | | | | X | | | | | | X | | | | | | X | | | | | | | | |
Todd Schermerhorn | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
Brooke Story | | | | | X | | | | | | X | | | | | | X | | | | | | | | |
Peter Wilver | | | | | X | | | | | | X | | | | | | X | | | | | | X | | |
| FRANCESCO BIANCHI | | ||||||
| INDEPENDENT Age (since 2015) | | | Francesco Bianchi has served as Chair of Seven Capital Partners S.r.l., a financial consulting firm, since June 2018. He previously served as the Chief Executive Officer of Seven Capital Partners and has been with the firm since 2013. Mr. Bianchi has 30 years of mergers and acquisitions and strategic advisory experience working for well-recognized international financial institutions including JPMorgan Chase (Paris), Morgan Grenfell (London), Citi (Milan) and Bankers Trust (Milan), where he served in various roles including general manager and head of the mergers and acquisitions and corporate finance division. He also headed the strategic planning division of Banca-Intesa S.p.A. in Italy and abroad. Mr. Bianchi earned a degree in economic sciences with honors from the University of Florence and is a chartered accountant. | | |||
| Committees: • Audit and Compliance; Compensation | | | Director Skills and Qualifications: • Mr. Bianchi is an audit committee financial expert and has an extensive professional background working in strategy and mergers and acquisitions. | |
| STACY ENXING SENG | | ||||||
| INDEPENDENT Age service (since 2019) | | | Stacy Enxing Seng has served as an Operating Partner with Lightstone Ventures, a venture capital group focused on medical technology and biotechnology-related investments, since 2016. Prior to joining Lightstone Ventures, Ms. Enxing Seng was with Covidien, a global health care products company, as its President, Vascular Therapies (2011 to 2014) and President of Peripheral Vascular (2010 to 2011). Ms. Enxing Seng joined Covidien in 2010 through the | | |||
| Committees: • Compensation (Chair) Other Current Public Company Directorships: • Sonova Holding AG Former Public Company Directorships During the Past Five Years: | | | Director Skills and Qualifications: • Ms. Enxing Seng has broad experience as a former senior executive responsible for a world-wide business unit of a major medical device company. In addition, she has significant experience as a co-founder of a successful medical device start-up. Her operational experience at both large and small medical device companies, combined with her first-hand experience gained from building ev3 from the ground up, provide the Board with valuable insights into strategy, marketing, sales, innovation, mergers and acquisitions and a variety of other medical device-related areas. | |
| WILLIAM KOZY | | ||||||
| Age (since 2018) | | | | ||||
| Committees: • None, as Other Current Public Company • Cooper Companies, Inc. | | | Director Skills and Qualifications: • Mr. Kozy serves as the Interim CEO of the Company and has a career spanning more than 40 years with global medical device companies. Prior to serving as COO for Becton Dickinson, Mr. Kozy’s key business worldwide leadership roles included responsibility for the Biosciences, Diagnostic and Medical segments of Becton Dickinson. During his time at Becton Dickinson, he was responsible for all world-wide businesses of the company with leadership emphasis on profitable revenue growth and talent development. He also brings a depth of corporate leadership experience in the areas of innovation systems, operations, manufacturing and ERP implementation as well as his broad and relevant experience in global strategy, mergers and acquisitions, technology and product development. | |
| | |||||||
| INDEPENDENT Age (since | | | |||||
| ||||||||
| Committees: • Nominating and Corporate Governance Other Current Public Company • ViewRay, Inc. | | | Director Skills and Qualifications: • Mr. Moore has extensive experience working with cutting edge medical device companies, including leadership of Cyberonics. He has significant experience in domestic and international general management and sales and marketing. Mr. Moore serves or has served on the boards of several medical device companies, the Epilepsy Foundation of America and other non-profits focused on epilepsy, the Medical Device Manufacturers Association and the Advisory Board of Purdue University’s Weldon School of Biomedical Engineering. | |
| DR. SHARON O’KANE | | ||||||
| INDEPENDENT Lead Director Age (since 2015) | | | | ||||
| Committees: • Nominating and Corporate Governance (Chair) | | | Director Skills and Qualifications: • Dr. O’Kane has extensive experience in healthcare, both in the academic and government realms and in research and development (R&D) capacities. She has served on the board of directors of several biotech and healthcare companies and organizations and has held numerous positions advising healthcare and biotech companies, governmental bodies and universities. Dr. O’Kane was also a co-founder, Chief Scientific Officer and executive director of Renovo Group Plc and was responsible for growing the university spin-out to a public company, and a non-executive director of Iomet Pharma Ltd. Dr. O’Kane received corporate director governance training at the Institute of Directors and Harvard Business School. | |
| ANDREA SAIA | | ||||||
| INDEPENDENT Age (since 2016) | | | | ||||
| Committees: • Audit and Compliance; Nominating and Corporate Governance Other Current Public Company • Align Technology, Inc. | | | Director Skills and Qualifications: • Ms. Saia is an accomplished global business executive with nearly 40 years’ experience in the medical device and consumer products industries including multinational companies such as Novartis, Unilever, Revlon and Procter & Gamble, and continuing involvement in business matters as a member of the Miami University Farmer School of Business Advisory Board. She has extensive global business experience, a broad understanding of healthcare, medical device and consumer products industries, strong management skills and significant operations experience. | |
| TODD SCHERMERHORN | | ||||||
| INDEPENDENT Age (since 2020) | | | | ||||
| Committees: • Audit and Compliance (Chair) Other Current Public Company Directorships: • The Travelers Companies, Inc. Former Public Company Directorships During the Past Five Years: • The | | | Director Skills and Qualifications: • Mr. Schermerhorn served as the Chief Financial Officer of a publicly traded company and has significant experience and expertise in management, accounting and business operations. Mr. Schermerhorn is also an audit committee financial expert. | |
| | |||||||
| INDEPENDENT Age Less than one year of service (since 2022) | | | | ||||
| Committees: • Nominating and Corporate Governance Former Public Company Directorships During the Past Five Years: • Sigilon Therapeutics | | | Director Skills and Qualifications: • Ms. Story has over 20 years of experience in the global medical technology industry. Throughout her career, she has excelled in helping large medical device corporations inspire teams, mentor and development talent and deliver economic value. | |
| PETER WILVER | | ||||||
| INDEPENDENT Age 63 One year of service (since 2022) | | | Peter Wilver served as Executive Vice President and Chief Administrative Officer of Thermo Fisher Scientific Inc., a provider of laboratory products and services, | | |||
| Committees: • Audit and Compliance; Compensation Other Current Public Company Directorships: • Baxter International Inc., Evoqua Water Technologies Corporation and Shoals Technology Group Former Public Company Directorships During the Past Five Years: • | | | Director Skills and Qualifications: • Mr. Wilver served as the Chief Financial Officer of a publicly traded company and has significant experience and expertise in strategic planning and business development, as well as in leading the financial, accounting and investor functions of large, multinational manufacturing companies. Mr. Wilver is also an audit committee financial expert. | |
Name | | | Fees Earned in Cash ($) | | | Stock Awards ($)(8) | | | Total ($) | | |||||||||
William Kozy(1) | | | | | 154,481 | | | | | | 184,991 | | | | | | 339,472 | | |
Daniel Moore(2) | | | | | 146,519 | | | | | | 109,982 | | | | | | 256,501 | | |
Todd Schermerhorn(3) | | | | | 133,365 | | | | | | 109,982 | | | | | | 243,347 | | |
Francesco Bianchi . | | | | | 133,000 | | | | | | 109,982 | | | | | | 242,982 | | |
Alfred Novak . | | | | | 133,000 | | | | | | 109,982 | | | | | | 242,982 | | |
Andrea Saia(4) | | | | | 131,000 | | | | | | 109,982 | | | | | | 240,982 | | |
Dr. Sharon O’Kane . | | | | | 125,000 | | | | | | 109,982 | | | | | | 234,982 | | |
Stacy Enxing Seng(5) | | | | | 124,692 | | | | | | 109,982 | | | | | | 234,674 | | |
Dr. Arthur Rosenthal(6) | | | | | 123,308 | | | | | | 109,982 | | | | | | 233,290 | | |
Hugh Morrison(7) | | | | | 61,923 | | | | | | — | | | | | | 61,923 | | |
Name | | | Fees Earned in Cash ($) | | | Stock Awards ($)(1) | | | Total ($) | | |||||||||
William Kozy(2) | | | | | 185,000 | | | | | | 204,987 | | | | | | 389,987 | | |
Francesco Bianchi | | | | | 133,000 | | | | | | 129,958 | | | | | | 262,958 | | |
Stacy Enxing Seng | | | | | 130,000 | | | | | | 129,958 | | | | | | 259,958 | | |
Daniel Moore | | | | | 117,099 | | | | | | 129,958 | | | | | | 247,057 | | |
Alfred Novak(3) | | | | | 60,288 | | | | | | — | | | | | | 60,288 | | |
Dr. Sharon O’Kane | | | | | 127,747 | | | | | | 129,958 | | | | | | 257,705 | | |
Dr. Arthur Rosenthal(3) | | | | | 53,489 | | | | | | — | | | | | | 53,489 | | |
Andrea Saia | | | | | 132,099 | | | | | | 129,958 | | | | | | 262,057 | | |
Todd Schermerhorn | | | | | 140,000 | | | | | | 129,958 | | | | | | 269,958 | | |
Brooke Story | | | | | 34,630 | | | | | | 96,134 | | | | | | 130,764 | | |
Peter Wilver | | | | | 73,077 | | | | | | 129,958 | | | | | | 203,035 | | |
Name | | | Age | | | Position | | |||
| | | | | | | Interim Chief Executive Officer | | ||
Alex Shvartsburg | | | | | 53 | | | | Chief Financial Officer | |
Michael Hutchinson | | | | | 52 | | | | Senior Vice President, Chief | |
| | | | | | | | |||
| | | | | | | ||||
Chief Human Resources Officer | |
| 2022 Short-Term Incentive Plan | | | Flow Performance Stock Units (PSUs) | | | 2020-2022 Relative TSR Performance Stock Units (PSUs) | | | |
| | Reflects performance against a set of financial and non-financial objectives | | | 30.7% of target Reflects 65.3% achievement against our target | | | 73% of target Reflects 41st percentile performance against our rTSR peer group | | |
| | What We DO: | | | | What We DO NOT Do: | | |
| | Target NEO pay around the market median to attract, motivate and retain talented executive officers with the skills and experience to ensure our long-term success | | | | We | | |
| | What We DO: | | | | What We DO NOT Do: | | |
| | Use multiple pay and award vehicles that work together to reward performance and retain talent, while maintaining alignment with shareholder interests | | | | We | | |
| | Reward individual performance with base salary and a cash-based short-term bonus while ensuring a meaningful link to our operational performance and shareholder interests | | | | We | | |
| | Balance the components of compensation so that short-term (annual) and long-term performance objectives are recognized because our success depends on our executive officers being focused on critical strategic and tactical objectives, both in the short-term and long-term | | | | We | | |
| | Pay a substantial portion of each NEO’s compensation as variable pay contingent upon the achievement of our business objectives | | | | | | |
| | Require NEOs to have a meaningful ownership interest in the Company with stock ownership requirements | | | | | | |
| | Vest equity awards over time to promote retention and mitigate risks | | | | | | |
| | | | | | | |
| • Abiomed, | | | • Integra LifeSciences Holdings Corporation | |
| • Avanos Medical, Inc. | | | • Masimo Corporation | |
| • CONMED Corporation | | | • Merit Medical Systems, Inc. | |
| • Globus Medical, Inc. | | | • Nevro Corp. | |
| • Haemonetics Corporation | | | • NuVasive, Inc. | |
| • ICU Medical, Inc. | | | • Penumbra, Inc. | |
| • Integer Holdings, Corporation | | | ||
• Tandem Diabetics Care, Inc. | | ||||
|
| | Currency | | 2021 Base Salary (local currency) | | 2020 Base Salary (local currency)(1) | | Change from 2020 | | 2021 Base Salary ($)(2) | | 2020 Base Salary ($)(2) | | | Currency | | 2022 Base Salary (local currency)(1) | | 2021 Base Salary (local currency)(1) | | Change from 2021 | | 2022 Base Salary ($)(1,2) | | 2021 Base Salary ($)(1,2) | | ||||||||||||||||||||||||||||||||||||||||||||||||
Damien McDonald | | | | GBP | | | | | 768,075 | | | | | 768,075 | | | | | 0% | | | | | 1,056,456 | | | | | 985,394 | | | | | | GBP | | | | | 791,117 | | | | | 768,075 | | | | | 3.0% | | | | | 974,545 | | | | | 1,056,456 | | | ||||||||||||
Alex Shvartsburg | | | | GBP | | | | | 330,000 | | | | | 242,050 | | | | | 36% | | | | | 453,898 | | | | | 310,535 | | | | | | GBP | | | | | 360,000 | | | | | 330,000 | | | | | 9.1% | | | | | 443,470 | | | | | 453,902 | | | ||||||||||||
Marco Dolci | | | | EUR | | | | | 500,000 | | | | | 500,000 | | | | | 0% | | | | | 591,140 | | | | | 570,190 | | | | | | EUR | | | | | 515,000 | | | | | 500,000 | | | | | 3.0% | | | | | 541,255 | | | | | 591,140 | | | ||||||||||||
Keyna Skeffington | | | | GBP | | | | | 360,400 | | | | | 360,400 | | | | | 0% | | | | | 495,712 | | | | | 462,372 | | | | | | GBP | | | | | 371,212 | | | | | 360,400 | | | | | 3.0% | | | | | 457,281 | | | | | 495,716 | | | ||||||||||||
Trui Hebbelinck | | | | GBP | | | | | 300,000 | | | | | 300,000 | | | | | 0% | | | | | 412,635 | | | | | 384,882 | | | | | | GBP | | | | | 309,000 | | | | | 300,000 | | | | | 3.0% | | | | | 380,645 | | | | | 412,638 | | |
Name | | 2021 STIP Minimum (Percentage of Base Salary) | | 2021 STIP Target (Percentage of Base Salary) | | 2021 STIP Maximum (Percentage of Base Salary)(1) | | | 2022 STIP Minimum (Percentage of Base Salary) | | 2022 STIP Target (Percentage of Base Salary) | | 2022 STIP Maximum (Percentage of Base Salary)(1) | | ||||||||||||||||||||||||
Damien McDonald | | | | 0% | | | | | 125% | | | | | 200.0% | | | | | | 0% | | | | | 125% | | | | | 200.0% | | | ||||||
Alex Shvartsburg | | | | 0% | | | | | 65% | | | | | 121.9% | | | | | | 0% | | | | | 65% | | | | | 121.9% | | | ||||||
Marco Dolci | | | | 0% | | | | | 60% | | | | | 112.5% | | | | | | 0% | | | | | 65% | | | | | 121.9% | | | ||||||
Keyna Skeffington | | | | 0% | | | | | 70% | | | | | 131.2% | | | | | | 0% | | | | | 70% | | | | | 131.2% | | | ||||||
Trui Hebbelinck | | | | 0% | | | | | 65% | | | | | 121.9% | | | | | | 0% | | | | | 65% | | | | | 121.9% | | |
Objective | | | Target ($) | | | Achievement ($) | | | Achievement (%) | | | Financial Payout (%) | | ||||||||||||
Net Sales | | | | | 950M | | | | | | 1,033.5M | | | | | | 108.8 | | | | | | 144 | | |
Adjusted Net Income | | | | | 76.7M | | | | | | 106.7M | | | | | | 139.1 | | | | | | 150 | | |
| | | Weight (%) | | | Target ($M) | | | Achievement ($M) | | | Achievement (%) | | | Financial Payout (%) | | |||||||||||||||
Net Sales | | | | | 60 | | | | | | 1,047.1 | | | | | | 1,070.4 | | | | | | 102.2% | | | | | | 111.1% | | |
Adjusted Net Income | | | | | 40 | | | | | | 143.8 | | | | | | 129.2 | | | | | | 89.8% | | | | | | 61.9% | | |
| | | | | | | | | | | | | | | | | | | | | LIVN Fin. PF | | | | | 91.4% | | |
| | | Weight (%) | | | Target ($M) | | | Achievement ($M) | | | Achievement (%) | | | Financial Payout (%) | | |||||||||||||||
Net Sales | | | | | 60 | | | | | | 491.3 | | | | | | 535.1 | | | | | | 108.9% | | | | | | 144.6% | | |
Adjusted Operating Income | | | | | 40 | | | | | | 70.7 | | | | | | 73.6 | | | | | | 104.1% | | | | | | 110.2% | | |
| | | | | | | | | | | | | | | | | | | | | CP BU Fin. PF | | | | | 130.8% | | |
Objectives | | | Weight (%) | | | Achievement (%) | | | Weighted Achievement (%) | | | Non-Financial Payout (%) | | ||||||||||||
Clinical Study Projects(1) | | | | | 50 | | | | | | 50 | | | | | | 25 | | | | | | | | |
Regulatory Project | | | | | 20 | | | | | | 0 | | | | | | 0 | | | | | | | | |
Publication Goal(2) | | | | | 20 | | | | | | 75 | | | | | | 15 | | | | | | | | |
Product Development(1) | | | | | 10 | | | | | | 50 | | | | | | 5 | | | | | | | | |
Total | | | | | | | | | | | | | | | | | 45 | | | | | | 97.5 | | |
| | Business Area | | | Description | | | Achievement | | | Achievement description | | | Weight (%) | | | Achievement (%)(1) | | |
| | DTD | | | First interim analysis completed for the Unipolar cohort by target date | | | Achieved | | | 250th Unipolar patient randomized into the study by target date which triggered the first interim analysis | | | 15% | | | 15% | | |
| | | | | First interim analysis initiated for Bipolar cohort in the RECOVER study upon randomizing target number of bipolar patients by target date | | | Not Achieved | | | Target number of bipolar patients unmet due to focus on achieving a successful Unipolar interim analysis. | | | 10% | | | 0% | | |
| | HF | | | First interim analysis completed by end target date | | | Achieved | | | Interim analysis completed by target date | | | 10% | | | 10% | | |
| | | | | Either — Pre-Market Approval (PMA) Clinical Module submitted by target date (if first IA hits criteria); or — Randomized target patients by target date | | | Achieved | | | Because the conditions for PMA filing were not met at the initial interim analysis, this goal becomes “Randomize target patients by target date.” The target number of randomized have been achieved by the target date. | | | 5% | | | 5% | | |
| | Business Area | | | Description | | | Achievement | | | Achievement description | | | Weight (%) | | | Achievement (%)(1) | | |
| | OSA | | | Target number of randomized patients by target date | | | Not Achieved | | | Target number of patients not achieved by the target date | | | 10% | | | 0% | | |
| | Epilepsy | | | Three key milestones in R&D to be completed by target date, each weighted 5%. | | | Achieved | | | All milestones achieved by the target date | | | 15% | | | 15% | | |
| | CP | | | Essenz CE Mark submission completed by target date | | | Achieved | | | Essenz CE Mark was submitted by target date | | | 10% | | | 10% | | |
| | | | | Essenz FDA submission completed by target date | | | Achieved | | | Essenz CE Mark was submitted by target date | | | 10% | | | 10% | | |
| | ACS | | | 510K regulatory clearance of LifeSPARC pump ECMO, Cannula and Oxygenator by target date, each weighted 5% | | | Not Achieved | | | Clearance was either obtained after the target date or not obtained | | | 15% | | | 0% | | |
| | Total | | | | | | | | | | | | 100% | | | 65% | | |
| | 2021 Target Bonus ($)(1) | | BPF | | 2021 Bonus payout ($)(1)(2) | | | 2022 STIP Target ($)(1) | | STIP Payout % | | 2022 STIP Payout ($)(1) | | ||||||||||||||||||||||||
Damien McDonald | | | | 1,320,571 | | | | | 142.7% | | | | | 1,884,454 | | | | | | 1,209,433 | | | | | 91.4% | | | | | 1,105,422 | | | ||||||
Alex Shvartsburg | | | | 220,359 | | | | | 142.7% | | | | | 314,453 | | | | | | 282,332 | | | | | 91.4% | | | | | 285,051 | | | ||||||
Marco Dolci | | | | 354,685 | | | | | 142.7% | | | | | 506,136 | | | | | | 342,810 | | | | | 119.0% | | | | | 407,944 | | | ||||||
Keyna Skeffington | | | | 347,001 | | | | | 142.7% | | | | | 495,170 | | | | | | 317,798 | | | | | 91.4% | | | | | 290,467 | | | ||||||
Trui Hebbelinck | | | | 268,215 | | | | | 142.7% | | | | | 382,742 | | | | | | 245,642 | | | | | 91.4% | | | | | 224,517 | | |
| | RSUs ($) | | SARs ($) | | rTSR PSUs ($) | | FCF PSUs ($) | | ROIC PSUs ($) | | Total Award Value ($) | | | RSUs ($) | | SARs ($) | | rTSR PSUs ($) | | FCF PSUs ($) | | ROIC PSUs ($) | | Total Award Value ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||
Damien McDonald | | | | 1,500,000 | | | | | 1,250,000 | | | | | 1,500,000 | | | | | 750,000 | | | | | 750,000 | | | | | 5,750,000 | | | | | | 1,500,000 | | | | | 1,250,000 | | | | | 1,500,000 | | | | | 750,000 | | | | | 750,000 | | | | | 5,750,000 | | | ||||||||||||
Alex Shvartsburg | | | | 250,000 | | | | | 250,000 | | | | | 250,000 | | | | | 125,000 | | | | | 125,000 | | | | | 1,000,000 | | | | | | 300,000 | | | | | 300,000 | | | | | 300,000 | | | | | 150,000 | | | | | 150,000 | | | | | 1,200,000 | | | ||||||||||||
Marco Dolci | | | | 250,000 | | | | | 250,000 | | | | | 250,000 | | | | | 125,000 | | | | | 125,000 | | | | | 1,000,000 | | | | | | 250,000 | | | | | 250,000 | | | | | 250,000 | | | | | 125,000 | | | | | 125,000 | | | | | 1,000,000 | | | ||||||||||||
Keyna Skeffington | | | | 250,000 | | | | | 250,000 | | | | | 250,000 | | | | | 125,000 | | | | | 125,000 | | | | | 1,000,000 | | | | | | 250,000 | | | | | 250,000 | | | | | 250,000 | | | | | 125,000 | | | | | 125,000 | | | | | 1,000,000 | | | ||||||||||||
Trui Hebbelinck | | | | 200,000 | | | | | 200,000 | | | | | 200,000 | | | | | 100,000 | | | | | 100,000 | | | | | 800,000 | | | | | | 225,000 | | | | | 225,000 | | | | | 225,000 | | | | | 112,500 | | | | | 112,500 | | | | | 900,000 | | |
| TSR Performance Percentile Rank | | | Percent of Target PSUs Earned | | |||
| ≥90th | | | | | 200% | | |
| 80th | | | | | 150% | | |
| 50th | | | | | 100% | | |
| 30th | | | | | 40% | | |
| <30th | | | | | 0% | | |
| • Abiomed, Inc.* | | | • Insulet Corporation | | | • Nevro Corp. | |
| • Avanos Medical, Inc. | | | • Integer Holdings Corporation | | | • NuVasive, Inc. | |
| • Boston Scientific Corporation | | | • Integra LifeSciences Holdings Corp. | | | • Orthofix Medical Inc. | |
| • CONMED Corporation | | | • Invacare Corporation | | | • Penumbra Inc. | |
| • DexCom, Inc. | | | • iRhythm Technologies, Inc. | | | • ResMed Inc. | |
| • Edwards Lifesciences Corporation | | | | | | | |
| • Globus Medical, Inc. | | | • Masimo Corporation | | | • Smith & Nephew plc | |
| • Haemonetics Corporation | | | • Medtronic plc | | | • Tandem Diabetes Care, Inc. | |
| • Hologic, Inc. | | | • Merit Medical Systems, Inc. | | | • Teleflex Incorporated Intuitive Surgical, Inc. | |
| • ICU Medical, Inc. | | | • Natus Medical Incorporated* | ||||
| | |||||||
• Zimmer Biomet Holdings, Inc. | |
| FCF Achievement Relative to FCF Target(1) | | | Percent of Target PSUs Earned | | |||
| ≥150% | | | | | 200% | | |
| 125% | | | | | 150% | | |
| 100% | | | | | 100% | | |
| 60% | | | | | 20% | | |
| <60% | | | | | 0% | | |
| ROIC Achievement Relative to ROIC Target(1) | | | Percent of Target PSUs Earned | | |||
| Target ≥ +250 bps | | | | | 200% | | |
| Target +125 bps | | | | | 150% | | |
| Target | | | | | 100% | | |
| Target – 125 bps | | | | | 50% | | |
| Target < 250 bps | | | | | 0% | | |
Name and Principal Position | | | Year | | | Salary ($)(1) | | | Stock Awards ($)(2) | | | Option Awards ($)(2) | | | Non-Equity Incentive Plan Compensation ($)(1)(3) | | | All Other Compensation ($)(1)(4) | | | Total | | |||||||||||||||||||||
Damien McDonald, | | | | | 2021 | | | | | | 1,056,456 | | | | | | 5,349,239 | | | | | | 1,249,971 | | | | | | 1,884,453 | | | | | | 540,525 | | | | | | 10,080,644 | | |
CEO | | | | | 2020 | | | | | | 973,663 | | | | | | 4,371,196 | | | | | | 1,249,834 | | | | | | — | | | | | | 307,660 | | | | | | 6,902,353 | | |
| | | | | 2019 | | | | | | 933,202 | | | | | | 4,309,277 | | | | | | 1,249,978 | | | | | | 277,244 | | | | | | 362,226 | | | | | | 7,131,927 | | |
Alex Shvartsburg, | | | | | 2021 | | | | | | 431,476 | | | | | | 891,335 | | | | | | 249,988 | | | | | | 314,453 | | | | | | 142,107 | | | | | | 2,029,359 | | |
CFO | | | | | 2020 | | | | | | 321,104 | | | | | | 572,817 | | | | | | 122,923 | | | | | | 46,243 | | | | | | 77,942 | | | | | | 1,141,029 | | |
Marco Dolci, | | | | | 2021 | | | | | | 591,140 | | | | | | 891,335 | | | | | | 249,988 | | | | | | 506,134 | | | | | | 190,807 | | | | | | 2,429,404 | | |
President, Cardiopulmonary BU | | | | | 2020 | | | | | | 570,190 | | | | | | 728,427 | | | | | | 249,960 | | | | | | 51,317 | | | | | | 122,641 | | | | | | 1,722,535 | | |
Keyna Skeffington, | | | | | 2021 | | | | | | 495,716 | | | | | | 891,335 | | | | | | 249,988 | | | | | | 495,170 | | | | | | 198,150 | | | | | | 2,330,359 | | |
SVP and General Counsel | | | | | 2020 | | | | | | 455,828 | | | | | | 728,427 | | | | | | 249,961 | | | | | | 47,866 | | | | | | 119,585 | | | | | | 1,601,667 | | |
Trui Hebbelinck, | | | | | 2019 | | | | | | 424,183 | | | | | | 683,719 | | | | | | 224,988 | | | | | | 106,289 | | | | | | 128,751 | | | | | | 1,567,930 | | |
CHRO | | | | | 2021 | | | | | | 412,638 | | | | | | 713,172 | | | | | | 199,973 | | | | | | 382,742 | | | | | | 149,940 | | | | | | 1,858,465 | | |
Name and Principal Position | | | Year | | | Salary ($)(1) | | | Stock Awards ($)(2) | | | Option Awards ($)(2) | | | Non-Equity Incentive Plan Compensation ($)(1)(3) | | | All Other Compensation ($)(1)(4) | | | Total | | |||||||||||||||||||||
Damien McDonald, Former CEO(5) | | | | | 2022 | | | | | | 967,450 | | | | | | 4,883,235 | | | | | | 1,249,995 | | | | | | 1,105,422 | | | | | | 359,443 | | | | | | 8,565,545 | | |
| | | 2021 | | | | | | 1,056,456 | | | | | | 5,349,239 | | | | | | 1,249,971 | | | | | | 1,884,453 | | | | | | 540,525 | | | | | | 10,080,644 | | | ||
| | | 2020 | | | | | | 973,663 | | | | | | 4,371,196 | | | | | | 1,249,834 | | | | | | — | | | | | | 307,660 | | | | | | 6,902,353 | | | ||
Alex Shvartsburg, CFO | | | | | 2022 | | | | | | 434,231 | | | | | | 976,502 | | | | | | 299,966 | | | | | | 258,051 | | | | | | 159,916 | | | | | | 2,128,666 | | |
| | | 2021 | | | | | | 431,476 | | | | | | 891,335 | | | | | | 249,988 | | | | | | 314,453 | | | | | | 142,107 | | | | | | 2,029,359 | | | ||
| | | 2020 | | | | | | 321,104 | | | | | | 572,817 | | | | | | 122,923 | | | | | | 46,243 | | | | | | 77,942 | | | | | | 1,141,029 | | | ||
Marco Dolci, President, Cardiopulmonary BU | | | | | 2022 | | | | | | 537,617 | | | | | | 813,760 | | | | | | 249,978 | | | | | | 407,944 | | | | | | 198,728 | | | | | | 2,208,027 | | |
| | | 2021 | | | | | | 591,140 | | | | | | 891,335 | | | | | | 249,988 | | | | | | 506,134 | | | | | | 190,807 | | | | | | 2,429,404 | | | ||
| | | 2020 | | | | | | 570,190 | | | | | | 728,427 | | | | | | 249,960 | | | | | | 51,317 | | | | | | 122,641 | | | | | | 1,722,535 | | | ||
Keyna Skeffington, Senior Advisor and Former SVP and General Counsel(6) | | | | | 2022 | | | | | | 453,951 | | | | | | 870,191 | | | | | | 508,982 | | | | | | 290,467 | | | | | | 155,927 | | | | | | 2,279,518 | | |
| | | 2021 | | | | | | 495,716 | | | | | | 891,335 | | | | | | 249,988 | | | | | | 495,170 | | | | | | 198,150 | | | | | | 2,330,359 | | | ||
| | | 2020 | | | | | | 455,828 | | | | | | 728,427 | | | | | | 249,961 | | | | | | 47,866 | | | | | | 119,585 | | | | | | 1,601,667 | | | ||
Trui Hebbelinck, CHRO | | | | | 2022 | | | | | | 377,873 | | | | | | 732,378 | | | | | | 224,966 | | | | | | 224,516 | | | | | | 129,018 | | | | | | 1,688,751 | | |
| | | 2021 | | | | | | 412,638 | | | | | | 713,172 | | | | | | 199,973 | | | | | | 382,742 | | | | | | 149,940 | | | | | | 1,858,465 | | |
Name | | PSUs — Probable Outcome of Performance Conditions PSUs Grant-Date Value ($) | | PSUs — Maximum Outcome of Performance Conditions Grant-Date Fair Value ($) | | | PSUs — Probable Outcome of Performance Conditions PSUs Grant-Date Value ($) | | PSUs — Maximum Outcome of Performance Conditions Grant-Date Fair Value ($) | | ||||||||||||||||
Damien McDonald | | | | 3,849,298 | | | | | 6,000,000 | | | | | | 3,383,442 | | | | | 6,000,000 | | | ||||
Alex Shvartsburg | | | | 641,405 | | | | | 1,000,000 | | | | | | 599,938 | | | | | 1,200,000 | | | ||||
Marco Dolci | | | | 641,405 | | | | | 1,000,000 | | | | | | 563,890 | | | | | 1,000,000 | | | ||||
Keyna Skeffington | | | | 641,405 | | | | | 1,000,000 | | | | | | 263,890 | | | | | 1,000,000 | | | ||||
Trui Hebbelinck | | | | 513,199 | | | | | 800,000 | | | | | | 507,470 | | | | | 900,000 | | |
Name | | rTSR PSUs Value Based on Grant Date Stock Price ($) | | rTSR PSUs — Value included in Summary Compensation Table ($) | | | rTSR PSUs Value Based on Grant Date Stock Price ($) | | rTSR PSUs — Value included in Summary Compensation Table ($) | | ||||||||||||||||
Damien McDonald | | | | 1,500,000 | | | | | 2,349,431 | | | | | | 1,500,000 | | | | | 1,883,441 | | | ||||
Alex Shvartsburg | | | | 250,000 | | | | | 391,476 | | | | | | 300,000 | | | | | 376,626 | | | ||||
Marco Dolci | | | | 250,000 | | | | | 391,476 | | | | | | 250,000 | | | | | 313,890 | | | ||||
Keyna Skeffington | | | | 250,000 | | | | | 391,476 | | | | | | 250,000 | | | | | 313,890 | | | ||||
Trui Hebbelinck | | | | 200,000 | | | | | 313,227 | | | | | | 225,000 | | | | | 282,470 | | |
Name | | | Supplemental Health Insurance ($) | | | Housing Allowance ($)(a) | | | Car Allowance ($)(b) | | | Defined Contribution Plan — Registrant Contributions ($)(c) | | | Cash in Lieu of Pension ($)(d) | | | Other ($)(e) | | | Total ($) | | |||||||||||||||||||||
Damien McDonald | | | | | 40,447 | | | | | | 41,264 | | | | | | 24,414 | | | | | | 5,502 | | | | | | 380,108 | | | | | | 48,790 | | | | | | 540,525 | | |
Alex Shvartsburg | | | | | 27,781 | | | | | | — | | | | | | 16,230 | | | | | | — | | | | | | 92,546 | | | | | | 5,550 | | | | | | 142,107 | | |
Marco Dolci | | | | | 4,561 | | | | | | — | | | | | | 17,025 | | | | | | 131,798 | | | | | | — | | | | | | 37,423 | | | | | | 190,807 | | |
Keyna Skeffington | | | | | 45,095 | | | | | | — | | | | | | 18,155 | | | | | | — | | | | | | 129,900 | | | | | | 5,000 | | | | | | 198,150 | | |
Trui Hebbelinck | | | | | 12,653 | | | | | | — | | | | | | 18,155 | | | | | | 119,132 | | | | | | — | | | | | | — | | | | | | 149,940 | | |
Name | | | Supplemental Health Insurance ($) | | | Car Allowance ($)(a) | | | Contribution Plan — Registrant Contributions ($)(b) | | | Cash in lieu of pension ($)(c) | | | Other ($)(d) | | | Total ($) | | ||||||||||||||||||
Damien McDonald | | | | | 40,240 | | | | | | 21,865 | | | | | | 4,927 | | | | | | 272,411 | | | | | | 20,000 | | | | | | 359,443 | | |
Alex Shvartsburg | | | | | 27,776 | | | | | | 16,261 | | | | | | — | | | | | | 90,879 | | | | | | 25,000 | | | | | | 159,916 | | |
Marco Dolci | | | | | 5,589 | | | | | | 15,134 | | | | | | 145,812 | | | | | | — | | | | | | 32,193 | | | | | | 198,728 | | |
Keyna Skeffington | | | | | 36,926 | | | | | | 16,261 | | | | | | — | | | | | | 97,740 | | | | | | 5,000 | | | | | | 155,927 | | |
Trui Hebbelinck | | | | | 12,544 | | | | | | 16,261 | | | | | | 4,927 | | | | | | 95,286 | | | | | | — | | | | | | 129,018 | | |
Name | | Grant Date | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards | | Estimated Future Payouts Under Equity Incentive Plan: Performance Stock Units (PSUs) (#) | | | All Other Stock Awards: Number of Shares of Service Based RSUs (#) | | All Other Option Awards: Number of Securities Underlying SARs (#) | | Exercise or Base Price of SAR Awards ($/Sh) | | | | | | | | | Grant Date Fair Value of Stock and SAR Awards ($)(1) | | | Grant Date | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards | | Estimated Future Payouts Under Equity Incentive Plan: Performance Stock Units (PSUs) (#) | | | All Other Stock Awards: Number of Shares of Service Based RSUs (#) | | All Other Option Awards: Number of Securities Underlying SARs (#) | | Exercise or Base Price of SAR Awards ($/S) | | | | | | | | | Grant Date Fair Value of Stock and SAR Awards ($) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Threshold ($) | | Target ($) | | Maximum ($) | | Threshold (#) | | Target (#) | | Maximum (#) | | | | Threshold ($) | | Target ($) | | Maximum ($) | | Threshold ($) | | Target ($) | | Maximum ($) | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Damien McDonald | | | | | | | | | — | | | | | 1,320,561 | | | | | 2,112,898 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | — | | | | | 1,209,433 | | | | | 1,935,092 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 10,238 | | | | | 20,476 | | | | | | | | | | | | | | | | | | | | (2) | | | | | 749,934 | | | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | 9,141 | | | | | 18,282 | | | | | | | | | | | (2) | | | | | 749,928 | | | ||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 10,238 | | | | | 20,476 | | | | | | | | | | | | | | | | | | | | (3) | | | | | 749,934 | | | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | 9,141 | | | | | 18,282 | | | | | | | | | | | (3) | | | | | 749,928 | | | ||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 20,477 | | | | | 40,954 | | | | | | | | | | | | | | | | | | | | (4) | | | | | 2,349,431 | | | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | 18,283 | | | | | 36,566 | | | | | | | | | | | (4) | | | | | 1,883,442 | | | ||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 20,477 | | | | | | | | | | | | | | | | | | | | 1,499,940 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 42,186 | | | | | 73.25 | | | | | | | | | | 1,249,971 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alex Shvartsburg | | | | | | | | | — | | | | | 220,359 | | | | | 413,173 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | 3,412 | | | | | | | | | | | | | | | | | | | | (2) | | | | | 124,965 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | 3,412 | | | | | | | | | | | | | | | | | | | | (3) | | | | | 124,965 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | 6,824 | | | | | | | | | | | | | | | | | | | | (4) | | | | | 391,476 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | | | | | | | | | | | | | | | | 249,929 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,437 | | | | | 73.25 | | | | | | | | | | 249,988 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Marco Dolci | | | | | | | | | — | | | | | 354,685 | | | | | 665,034 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | 3,412 | | | | | | | | | | | | | | | | | | | | (2) | | | | | 124,965 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | 3,412 | | | | | | | | | | | | | | | | | | | | (3) | | | | | 124,965 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | 6,824 | | | | | | | | | | | | | | | | | | | | (4) | | | | | 391,476 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | | | | | | | | | | | | | | | | 249,929 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,437 | | | | | 73.25 | | | | | | | | | | 249,988 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Keyna Skeffington | | | | | | | | | — | | | | | 346,999 | | | | | 650,623 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | 3,412 | | | | | | | | | | | | | | | | | | | | (2) | | | | | 124,965 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | 3,412 | | | | | | | | | | | | | | | | | | | | (3) | | | | | 124,965 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | 6,824 | | | | | | | | | | | | | | | | | | | | (4) | | | | | 391,476 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | | | | | | | | | | | | | | | | 249,929 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,437 | | | | | 73.25 | | | | | | | | | | 249,988 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trui Hebbelinck | | | | | | | | | — | | | | | 268,215 | | | | | 502,903 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 1,365 | | | | | 2,730 | | | | | | | | | | | | | | | | | | | | (2) | | | | | 99,986 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 1,365 | | | | | 2,730 | | | | | | | | | | | | | | | | | | | | (3) | | | | | 99,986 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | 2,730 | | | | | 5,460 | | | | | | | | | | | | | | | | | | | | (4) | | | | | 313,227 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,730 | | | | | | | | | | | | | | | | | | | | 199,973 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 03/30/2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 6,749 | | | | | 73.25 | | | | | | | | | | 199,973 | | |
Name | | | Grant Date | | | Estimated Future Payouts Under Non-Equity Incentive Plan Awards | | | Estimated Future Payouts Under Equity Incentive Plan: Performance Stock Units (PSUs) (#) | | | All Other Stock Awards: Number of Shares of Service Based RSUs (#) | | | All Other Option Awards: Number of Securities Underlying SARs (#) | | | Exercise or Base Price of SAR Awards ($/S) | | | | | | | | | Grant Date Fair Value of Stock and SAR Awards ($) | | ||||||||||||||||||||||||||||||||||||||||||
| Threshold ($) | | | Target ($) | | | Maximum ($) | | | Threshold ($) | | | Target ($) | | | Maximum ($) | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 18,283 | | | | | | | | | | | | | | | | | | | | | | | | 1,499,937 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 35,483 | | | | | | 82.04 | | | | | | | | | | | | 1,249,995 | | |
Alex Shvartsburg | | | | | | | | | | | — | | | | | | 282,332 | | | | | | 527,962 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,828 | | | | | | 3,656 | | | | | | | | | | | | | | | | | | | | | | | | (2) | | | | | | 149,969 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,828 | | | | | | 3,656 | | | | | | | | | | | | | | | | | | | | | | | | (3) | | | | | | 149,969 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,656 | | | | | | 7,312 | | | | | | | | | | | | | | | | | | | | | | | | (4) | | | | | | 376,626 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,656 | | | | | | | | | | | | | | | | | | | | | | | | 299,938 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 8,515 | | | | | | 82.04 | | | | | | | | | | | | 299,966 | | |
Marco Dolci | | | | | | | | | | | — | | | | | | 342,811 | | | | | | 527.962 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,523 | | | | | | 3,046 | | | | | | | | | | | | | | | | | | | | | | | | (2) | | | | | | 124,947 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,523 | | | | | | 3,046 | | | | | | | | | | | | | | | | | | | | | | | | (3) | | | | | | 124,947 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,047 | | | | | | 6,094 | | | | | | | | | | | | | | | | | | | | | | | | (4) | | | | | | 313,890 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,047 | | | | | | | | | | | | | | | | | | | | | | | | 249,976 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 7,096 | | | | | | 82.04 | | | | | | | | | | | | 249,978 | | |
Keyna Skeffington | | | | | | | | | | | — | | | | | | 317,798 | | | | | | 594,282 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,523 | | | | | | 3,046 | | | | | | | | | | | | | | | | | | | | | | | | (2) | | | | | | 124,947 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,523 | | | | | | 3,046 | | | | | | | | | | | | | | | | | | | | | | | | (3) | | | | | | 124,947 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,047 | | | | | | 6,094 | | | | | | | | | | | | | | | | | | | | | | | | (4) | | | | | | 313,890 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,047 | | | | | | | | | | | | | | | | | | | | | | | | 249,976 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 7,096 | | | | | | 82.04 | | | | | | | | | | | | 249,978 | | |
| | | | | 12/31/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (5) | | | | | | 315,435 | | |
Trui Hebbelinck | | | | | | | | | | | — | | | | | | 245,643 | | | | | | 459,352 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,371 | | | | | | 2,742 | | | | | | | | | | | | | | | | | | | | | | | | (2) | | | | | | 112,477 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,371 | | | | | | 2,742 | | | | | | | | | | | | | | | | | | | | | | | | (3) | | | | | | 112,477 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,742 | | | | | | 5,484 | | | | | | | | | | | | | | | | | | | | | | | | (4) | | | | | | 282,470 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,742 | | | | | | | | | | | | | | | | | | | | | | | | 224,954 | | |
| | | | | 3/30/2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 6,386 | | | | | | 82.04 | | | | | | | | | | | | 224,966 | | |
Name | | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of Securities Underlying Unexercised Options (#) Exercisable(1) | | | Number of Securities Underlying Unexercised Options (#) Unexercisable(2) | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(3) | | | | | | | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(4) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested | | | | | | | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||||
Damien McDonald | | | | | 130,670 | | | | | | 0 | | | | | | 44.79 | | | | | | 11/4/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 31,134 | | | | | | 10,378 | | | | | | 88.38 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 19,679 | | | | | | 19,678 | | | | | | 97.25 | | | | | | 3/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 19,630 | | | | | | 58,887 | | | | | | 43.57 | | | | | | 3/30/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 0 | | | | | | 42,186 | | | | | | 73.25 | | | | | | 3/30/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,182 | | | | | | (5) | | | | | | 278,202 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 6,426 | | | | | | (6) | | | | | | 561,825 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 25,820 | | | | | | (7) | | | | | | 2,257,443 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 20,477 | | | | | | (8) | | | | | | 1,790,304 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,424 | | | | | | (9) | | | | | | 1,348,520 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,424 | | | | | | (10) | | | | | | 1,348,520 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 34,427 | | | | | | (11) | | | | | | 3,009,953 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 34,427 | | | | | | (12) | | | | | | 3,009,953 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,238 | | | | | | (13) | | | | | | 895,108 | | |
| | | | | | | | | | | | | | | �� | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 20,477 | | | | | | (14) | | | | | | 1,790,304 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 10,238 | | | | | | (15) | | | | | | 895,108 | | |
Name | | | Option Awards | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of Securities Underlying Unexercised Options (#) Exercisable(1) | | | Number of Securities Underlying Unexercised Options (#) Unexercisable(2) | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(3) | | | | | | | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(4) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested | | | | | | | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||||
Alex Shvartsburg | | | | | 5,833 | | | | | | 0 | | | | | | 80.26 | | | | | | 12/15/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 3,807 | | | | | | 1,269 | | | | | | 88.38 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2,437 | | | | | | 2,437 | | | | | | 97.25 | | | | | | 3/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 1,960 | | | | | | 5,878 | | | | | | 43.57 | | | | | | 3/30/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | 8,437 | | | | | | 73.25 | | | | | | 3/30/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 390 | | | | | | (5) | | | | | | 34,098 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 785 | | | | | | (6) | | | | | | 68,633 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,115 | | | | | | (7) | | | | | | 184,914 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | | (8) | | | | | | 298,311 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,730 | | | | | | (16) | | | | | | 413,544 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,839 | | | | | | (17) | | | | | | 160,784 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | | (13) | | | | | | 149,156 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | | (14) | | | | | | 298,311 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | | (15) | | | | | | 149,156 | | |
Marco Dolci | | | | | 5,447 | | | | | | 1,815 | | | | | | 88.38 | | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 3,190 | | | | | | 3,189 | | | | | | 97.25 | | | | | | 3/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | — | | | | | | 11,777 | | | | | | 43.57 | | | | | | 3/30/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | — | | | | | | 8,437 | | | | | | 73.25 | | | | | | 3/30/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 558 | | | | | | (5) | | | | | | 48,786 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,028 | | | | | | (6) | | | | | | 89,878 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,302 | | | | | | (7) | | | | | | 376,124 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | | (8) | | | | | | 298,311 | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,056 | | | | | | (9) | | | | | | 179,756 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,056 | | | | | | (10) | | | | | | 179,756 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,737 | | | | | | (11) | | | | | | 501,586 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,737 | | | | | | (12) | | | | | | 501,586 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | | (13) | | | | | | 149,156 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | | (14) | | | | | | 298,311 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | | (15) | | | | | | 149,156 | | |
Name | | | Number of Securities Underlying Unexercised Options (#) Exercisable(1) | | | Number of Securities Underlying Unexercised Options (#) Unexercisable(2) | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(3) | | | | | | | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(4) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||
Damien McDonald | | | | | 130,670 | | | | | | — | | | | | | 44.79 | | | | | | 11/04/2026 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | | | 41,512 | | | | | | — | | | | | | 88.38 | | | | | | 03/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 29,518 | | | | | | 9,839 | | | | | | 97.25 | | | | | | 03/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 39,259 | | | | | | 39,258 | | | | | | 43.57 | | | | | | 03/30/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 10,547 | | | | | | 31,639 | | | | | | 73.25 | | | | | | 03/30/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,213 | | | | | | (5) | | | | | | 178,450 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 17,213 | | | | | | (6) | | | | | | 956,010 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,357 | | | | | | (7) | | | | | | 852,928 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 18,283 | | | | | | (8) | | | | | | 1,015,438 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (9) | | | | | | | | | | | | 34,427 | | | | | | 1,912,076 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (10) | | | | | | | | | | | | 34,427 | | | | | | 1,912,076 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 20,476 | | | | | | (11) | | | | | | 1,137,237 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,490 | | | | | | (12) | | | | | | 860,315 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (13) | | | | | | | | | | | | 20,477 | | | | | | 1,137,293 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (14) | | | | | | | | | | | | 9,141 | | | | | | 507,691 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (15) | | | | | | | | | | | | 9,141 | | | | | | 507,691 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (16) | | | | | | | | | | | | 18,283 | | | | | | 1,015,438 | | |
Alex Shvartsburg | | | | | 5,833 | | | | | | 0 | | | | | | 80.26 | | | | | | 12/15/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||
| | | | | 5,076 | | | | | | 0 | | | | | | 88.38 | | | | | | 03/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 3,656 | | | | | | 1,218 | | | | | | 97.25 | | | | | | 03/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 3,919 | | | | | | 3,919 | | | | | | 43.57 | | | | | | 03/30/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 2,110 | | | | | | 6,327 | | | | | | 73.25 | | | | | | 03/30/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | 0 | | | | | | 8,515 | | | | | | 82.04 | | | | | | 03/30/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 392 | | | | | | (5) | | | | | | 21,772 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,410 | | | | | | (6) | | | | | | 78,311 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,153 | | | | | | (17) | | | | | | 175,118 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,226 | | | | | | (18) | | | | | | 68,092 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,559 | | | | | | (7) | | | | | | 142,127 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,656 | | | | | | (8) | | | | | | 203,054 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | | (11) | | | | | | 189,502 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,581 | | | | | | (12) | | | | | | 143,354 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (13) | | | | | | | | | | | | 3,412 | | | | | | 189,502 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (14) | | | | | | | | | | | | 1,828 | | | | | | 101,527 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (15) | | | | | | | | | | | | 1,828 | | | | | | 101,527 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (16) | | | | | | | | | | | | 3,656 | | | | | | 203,054 | | |
Name | | | Option Awards | | Stock Awards | | | Number of Securities Underlying Unexercised Options (#) Exercisable(1) | | Number of Securities Underlying Unexercised Options (#) Unexercisable(2) | | Option Exercise Price ($) | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#)(3) | | | | | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(4) | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of Securities Underlying Unexercised Options (#) Exercisable(1) | | Number of Securities Underlying Unexercised Options (#) Unexercisable(2) | | Option Exercise Price ($) | | Option Expiration Date | | Number of Shares or Units of Stock That Have Not Vested (#)(3) | | | | | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(4) | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested | | | | | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Marco Dolci | | | | 7,262 | | | | | 0 | | | | | 88.38 | | | | | 03/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 4,785 | | | | | 1,594 | | | | | 97.25 | | | | | 03/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 3,926 | | | | | 7,851 | | | | | 43.57 | | | | | 03/30/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2,110 | | | | | 6,327 | | | | | 73.25 | | | | | 03/30/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 0 | | | | | 7,096 | | | | | 82.04 | | | | | 03/30/2032 | | | | | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 514 | | | | | (5) | | | | | 28,548 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 2,868 | | | | | (6) | | | | | 159,289 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 2,559 | | | | | (7) | | | | | 142,127 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 3,047 | | | | | (8) | | | | | 169,230 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | (9) | | | | | | | | | | 5,737 | | | | | 318,633 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | (10) | | | | | | | | | | 5,737 | | | | | 318,633 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | (11) | | | | | 189,502 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 2,581 | | | | | (12) | | | | | 143,354 | | | | | | | | | | | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | (13) | | | | | | | | | | 3,412 | | | | | 189,502 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | (14) | | | | | | | | | | 1,523 | | | | | 84,587 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | (15) | | | | | | | | | | 1,523 | | | | | 84,587 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | (16) | | | | | | | | | | 3,047 | | | | | 169,230 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Keyna Skeffington | | | | 15,203 | | | | | — | | | | | 59.97 | | | | | 6/12/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 15,203 | | | | | 0 | | | | | 59.97 | | | | | 06/12/2027 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||
| | | | 4,497 | | | | | 1,499 | | | | | 88.38 | | | | | 3/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,996 | | | | | 0 | | | | | 88.38 | | | | | 03/15/2028 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||
| | | | 3,542 | | | | | 3,542 | | | | | 97.25 | | | | | 3/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,313 | | | | | 1,771 | | | | | 97.25 | | | | | 03/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||
| | | | 3,926 | | | | | 11,777 | | | | | 43.57 | | | | | 3/30/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 7,852 | | | | | 7,851 | | | | | 43.57 | | | | | 03/30/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||
| | | | — | | | | | 8,437 | | | | | 73.25 | | | | | 3/30/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,110 | | | | | 6,327 | | | | | 73.25 | | | | | 03/30/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 459 | | | | | (5) | | | | | 40,130 | | | | | | | | | | | | | | | | | | | | | 0 | | | | | 7,096 | | | | | 82.04 | | | | | 03/30/2032 | | | | | 578 | | | | | (5) | | | | | 32,102 | | | | | | | | | | | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 1,156 | | | | | (6) | | | | | 101,069 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,868 | | | | | (6) | | | | | 159,289 | | | | | | | | | | | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 4,302 | | | | | (7) | | | | | 376,124 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,559 | | | | | (7) | | | | | 142,127 | | | | | | | | | | | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | (8) | | | | | 298,311 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,047 | | | | | (8) | | | | | 169,230 | | | | | | | | | | | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 300 | | | | | (18) | | | | | 26,229 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (9) | | | | | | | | | | 5,737 | | | | | 318,633 | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,313 | | | | | (9) | | | | | 202,226 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (10) | | | | | | | | | | 5,737 | | | | | 318,633 | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,313 | | | | | (10) | | | | | 202,226 | | | | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | (11) | | | | | 189,502 | | | | | | | | | | | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,737 | | | | | (11) | | | | | 501,586 | | | | | | | | | | | | | | | | | | | | | | | | | | 2,581 | | | | | (12) | | | | | 143,354 | | | | | | | | | | | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 5,737 | | | | | (12) | | | | | 501,586 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (13) | | | | | | | | | | 3,412 | | | | | 189,502 | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | (13) | | | | | 149,156 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (14) | | | | | | | | | | 1,523 | | | | | 84,587 | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 3,412 | | | | | (14) | | | | | 298,311 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (15) | | | | | | | | | | 1,523 | | | | | 84,587 | | | |||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,706 | | | | | (15) | | | | | 149,156 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (16) | | | | | | | | | | 3,047 | | | | | 169,230 | | | |||||||||||||||||||
Trui Hebbelinck | | | | 2,592 | | | | | 2,591 | | | | | 97.25 | | | | | 3/30/2029 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 3,141 | | | | | 9,421 | | | | | 43.57 | | | | | 3/30/2030 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | — | | | | | 6,749 | | | | | 73.25 | | | | | 3/30/2031 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 835 | | | | | (6) | | | | | 73,004 | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 3,442 | | | | | (7) | | | | | 300,934 | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 2,730 | | | | | (8) | | | | | 238,684 | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | 880 | | | | | (19) | | | | | 76,938 | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,670 | | | | | (9) | | | | | 146,008 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,670 | | | | | (10) | | | | | 146,008 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,590 | | | | | (11) | | | | | 401,304 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 4,590 | | | | | (12) | | | | | 401,304 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,365 | | | | | (13) | | | | | 119,342 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,730 | | | | | (14) | | | | | 238,684 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,365 | | | | | (15) | | | | | 119,342 | | |
Name | | | Number of Securities Underlying Unexercised Options (#) Exercisable(1) | | | Number of Securities Underlying Unexercised Options (#) Unexercisable(2) | | | Option Exercise Price ($) | | | Option Expiration Date | | | Number of Shares or Units of Stock That Have Not Vested (#)(3) | | | | | | | | | Market Value of Shares or Units of Stock That Have Not Vested ($)(4) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||
Trui Hebbelinck | | | | | 3888 | | | | | | 1295 | | | | | | 97.25 | | | | | | 03/30/2029 | | | | | | 417 | | | | | | (5) | | | | | | 23,160 | | | | | | | | | | | | | | |
| | | | | 6281 | | | | | | 6281 | | | | | | 43.57 | | | | | | 03/30/2030 | | | | | | 440 | | | | | | (19) | | | | | | 24,438 | | | | | | | | | | | | | | |
| | | | | 1688 | | | | | | 5061 | | | | | | 73.25 | | | | | | 03/30/2031 | | | | | | 2,295 | | | | | | (6) | | | | | | 127,464 | | | | | | | | | | | | | | |
| | | | | 0 | | | | | | 6386 | | | | | | 82.04 | | | | | | 03/30/2032 | | | | | | 2,047 | | | | | | (7) | | | | | | 113,690 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,742 | | | | | | (8) | | | | | | 152,291 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (9) | | | | | | | | | | | | 4,590 | | | | | | 254,929 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (10) | | | | | | | | | | | | 4,590 | | | | | | 254,929 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,730 | | | | | | (11) | | | | | | 151,624 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | 2,065 | | | | | | (12) | | | | | | 114,701 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (13) | | | | | | | | | | | | 2,730 | | | | | | 151,624 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (14) | | | | | | | | | | | | 1,371 | | | | | | 76,145 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (15) | | | | | | | | | | | | 1,371 | | | | | | 76,145 | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (16) | | | | | | | | | | | | 2,742 | | | | | | 152,291 | | |
| | Stock Options | | Stock Shares | | | Stock Options | | Stock Shares | | ||||||||||||||||||||||||||||||||||
Name | | Number of LivaNova Option Shares Acquired on Exercise (#) | | Value Realized on Exercise ($) | | Number of LivaNova Shares Acquired on Vesting (#) | | Value Realized on Vesting ($)(1) | | | Number of Options Shares Acquired on Exercise (#) | | Value Realized on Exercise ($) | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting ($)(1) | | ||||||||||||||||||||||||||
Damien McDonald | | | | | | | | | | | | | | 40,079 | | | | | 3,066,827 | | | | | | | | | | 25,289 | | | | | 2,012,368 | | | ||||||||
Alex Shvartsburg | | | | | | | | | | | | | | 4,342 | | | | | 342,873 | | | | | | | | | | 4,531 | | | | | 315,288 | | | ||||||||
Marco Dolci | | | | 3,926 | | | | | 154,724 | | | | | 6,044 | | | | | 461,263 | | | | | | | | | | 4,047 | | | | | 322,192 | | | ||||||||
Keyna Skeffington | | | | | | | | | | | | | | 4,970 | | | | | 383,230 | | | | | | | | | | 4,398 | | | | | 343,886 | | | ||||||||
Trui Hebbelinck | | | | | | | | | | | | | | 2,005 | | | | | 152,477 | | | | | | | | | | 3,247 | | | | | 251,459 | | |
Type of Payment or Benefit(5) | | Termination without Cause(1) | | Separation due to Change in Control(2) | | Separation due to Disability(3) | | Separation due to Death(4) | | Separation due to Retirement | | | Termination without Cause(1) | | Separation due to Change in Control(2) | | Separation due to Disability(3) | | Separation due to Death(4) | | Separation due to Retirement | | ||||||||||||||||||||||||||||||||||||||||
Severance | | | $ | 1,289,391 | | | | | — | | | | | — | | | | $ | 4,225,823 | | | | | — | | | | | $ | 1,142,593 | | | | | — | | | | | — | | | | $ | 3,898,183 | | | | | — | | | ||||||||||
STIP | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||
LTIP | | | | — | | | | $ | 8,068,755 | | | | $ | 3,180,981 | | | | $ | 3,180,981 | | | | | — | | | | | | — | | | | $ | 5,470,296 | | | | $ | 469,918 | | | | $ | 469,918 | | | | | — | | | ||||||||||
Benefits | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||
Total | | | $ | 1,289,391 | | | | $ | 8,068,755 | | | | $ | 3,180,981 | | | | $ | 7,406,804 | | | | | — | | | | | $ | 1,142,593 | | | | $ | 5,470,296 | | | | $ | 469,918 | | | | $ | 4,368,101 | | | | | — | | |
Type of Payment or Benefit(5) | | | Termination without Cause(1) | | | Separation due to Change in Control(2) | | | Separation due to Disability(3) | | | Separation due to Death(4) | | | Separation due to Retirement | | |||||||||||||||
Severance | | | | $ | 453,902 | | | | | | — | | | | | | — | | | | | $ | 1,815,608 | | | | | | — | | |
STIP | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LTIP | | | | | — | | | | | $ | 1,537,729 | | | | | $ | 377,445 | | | | | $ | 377,445 | | | | | | — | | |
Benefits | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | $ | 453,902 | | | | | $ | 1,537,729 | | | | | $ | 377,445 | | | | | $ | 2,193,053 | | | | | | — | | |
Type of Payment or Benefit(5) | | | Termination without Cause(1) | | | Separation due to Change in Control(2) | | | Separation due to Disability(3) | | | Separation due to Death(4) | | | Separation due to Retirement | | |||||||||||||||
Severance | | | | $ | 443,470 | | | | | | — | | | | | | — | | | | | $ | 1,773,878 | | | | | | — | | |
STIP | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LTIP | | | | | — | | | | | $ | 1,068,241 | | | | | $ | 46,910 | | | | | $ | 46,910 | | | | | | — | | |
Benefits | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | $ | 443,470 | | | | | $ | 1,068,241 | | | | | $ | 46,910 | | | | | $ | 1,820,788 | | | | | | — | | |
Type of Payment or Benefit(5) | | | Termination without Cause(1) | | | Separation due to Change in Control(2) | | | Separation due to Disability(3) | | | Separation due to Death(4) | | | Separation due to Retirement | | |||||||||||||||
Severance | | | | $ | 771,582 | | | | | | — | | | | | | — | | | | | $ | 525,490 | | | | | | — | | |
STIP | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LTIP | | | | | — | | | | | $ | 926,027 | | | | | $ | 93,976 | | | | | $ | 93,976 | | | | | | — | | |
Benefits | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | $ | 746,759 | | | | | $ | 926,027 | | | | | $ | 93,976 | | | | | $ | 619,466 | | | | | | — | | |
Type of Payment or Benefit(5) | | | Termination without Cause(1) | | | Separation due to Change in Control(2) | | | Separation due to Disability(3) | | | Separation due to Death(4) | | | Separation due to Retirement | | |||||||||||||||
Severance | | | | $ | 457,281 | | | | | | — | | | | | | — | | | | | $ | 1,829,125 | | | | | | — | | |
STIP | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LTIP | | | | | — | | | | | $ | 929,581 | | | | | $ | 93,976 | | | | | $ | 93,976 | | | | | | — | | |
Benefits | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | $ | 457,281 | | | | | $ | 929,581 | | | | | $ | 636,176 | | | | | $ | 1,923,101 | | | | | | — | | |
Type of Payment or Benefit(5) | | | Termination without Cause(1) | | | Separation due to Change in Control(2) | | | Separation due to Disability(3) | | | Separation due to Death(4) | | | Separation due to Retirement | | |||||||||||||||
Severance | | | | $ | 746,759 | | | | | | — | | | | | | — | | | | | $ | 591,140 | | | | | | — | | |
STIP | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LTIP | | | | | — | | | | | $ | 1,449,275 | | | | | $ | 636,176 | | | | | $ | 636,176 | | | | | | — | | |
Benefits | | | | | — | | ��� | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | $ | 746,759 | | | | | $ | 1,449,275 | | | | | $ | 636,176 | | | | | $ | 1,227,316 | | | | | | — | | |
Type of Payment or Benefit(5) | | Termination without Cause(1) | | Separation due to Change in Control(2) | | Separation due to Disability(3) | | Separation due to Death(4) | | Separation due to Retirement | | | Termination without Cause(1) | | Separation due to Change in Control(2) | | Separation due to Disability(3) | | Separation due to Death(4) | | Separation due to Retirement | | ||||||||||||||||||||||||||||||||||||||||
Severance | | | $ | 495,716 | | | | | — | | | | | — | | | | $ | 1,982,864 | | | | | — | | | | | $ | 380,645 | | | | | — | | | | | — | | | | $ | 1,522,579 | | | | | — | | | ||||||||||
STIP | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||
LTIP | | | | — | | | | $ | 1,478,039 | | | | $ | 636,176 | | | | $ | 636,176 | | | | | — | | | | | | — | | | | $ | 782,552 | | | | $ | 75,184 | | | | $ | 75,184 | | | | | — | | | ||||||||||
Benefits | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||
Total | | | $ | 495,716 | | | | $ | 1,478,039 | | | | $ | 636,176 | | | | $ | 2,619,040 | | | | | — | | | | | $ | 380,645 | | | | $ | 782,552 | | | | $ | 508,906 | | | | $ | 1,597,763 | | | | | — | | |
Type of Payment or Benefit(5) | | | Termination without Cause(1) | | | Separation due to Change in Control(2) | | | Separation due to Disability(3) | | | Separation due to Death(4) | | | Separation due to Retirement | | |||||||||||||||
Severance | | | | $ | 412,638 | | | | | | — | | | | | | — | | | | | $ | 412,638 | | | | | | — | | |
STIP | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
LTIP | | | | | — | | | | | $ | 1,198,466 | | | | | $ | 508,906 | | | | | $ | 508,906 | | | | | | — | | |
Benefits | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | $ | 412,638 | | | | | $ | 1,198,466 | | | | | $ | 508,906 | | | | | $ | 921,544 | | | | | | — | | |
Year | | | Summary Compensation Table Total for PEO(1) | | | Compensation Actually Paid to PEO(2) | | | Average Summary Compensation Table Total for Non-PEO NEOs(3) | | | Average Compensation Actually Paid to Non-PEO NEOs(4) | | | Value of Initial Fixed $100 Investment Based On: | | | Net Income (millions)(7) | | | Adjusted Net Income (millions)(8) | | |||||||||||||||||||||||||||
| Total Shareholder Return(5) | | | Peer Group Total Shareholder Return(6) | | ||||||||||||||||||||||||||||||||||||||||||||
(a) | | | (b) | | | (c) | | | (d) | | | (e) | | | (f) | | | (g) | | | (h) | | | (i) | | ||||||||||||||||||||||||
2022 | | | | $ | 8,565,545 | | | | | -$ | 2,575,035 | | | | | $ | 2,076,241 | | | | | $ | 178,933 | | | | | $ | 73.63 | | | | | $ | 113.92 | | | | | -$ | 86.2 | | | | | $ | 129.2 | | |
2021 | | | | $ | 10,080,644 | | | | | $ | 15,281,126 | | | | | $ | 2,161,897 | | | | | $ | 3,038,616 | | | | | $ | 115.91 | | | | | $ | 140.40 | | | | | -$ | 135.8 | | | | | $ | 106.7 | | |
2020 | | | | $ | 6,902,353 | | | | | $ | 5,689,235 | | | | | $ | 1,730,387 | | | | | $ | 1,334,414 | | | | | $ | 87.78 | | | | | $ | 117.63 | | | | | -$ | 348.8 | | | | | $ | 59.0 | | |
Year | | | Reported Summary Compensation Table Total for PEO | | | Reported Value of Equity Awards(a) | | | Equity Award Adjustments(b)(c) | | | Compensation Actually Paid to PEO | | ||||||||||||
2022 | | | | $ | 8,565,545 | | | | | $ | 6,133,230 | | | | | -$ | 5,007,350 | | | | | -$ | 2,575,035 | | |
2021 | | | | $ | 10,080,644 | | | | | $ | 6,599,210 | | | | | $ | 11,799,692 | | | | | $ | 15,281,126 | | |
2020 | | | | $ | 6,902,353 | | | | | $ | 5,621,030 | | | | | $ | 4,407,912 | | | | | $ | 5,689,235 | | |
Year | | | Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year | | | Change in Fair Value of Equity Awards Granted in Prior Years that Remain Outstanding and Unvested as of Year End | | | Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year | | | Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year | | | Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year | | | Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation | | | Total Equity Award Adjustments | | |||||||||||||||||||||
2022 | | | | $ | 3,336,237 | | | | | -$ | 7,788,109 | | | | | | — | | | | | -$ | 555,478 | | | | | | — | | | | | | — | | | | | -$ | 5,007,350 | | |
2021 | | | | $ | 9,284,521 | | | | | $ | 2,130,242 | | | | | | — | | | | | $ | 384,929 | | | | | | — | | | | | | — | | | | | $ | 11,799,692 | | |
2020 | | | | $ | 9,046,834 | | | | | -$ | 2,535,954 | | | | | | — | | | | | -$ | 2,102,967 | | | | | | — | | | | | | — | | | | | $ | 4,407,912 | | |
Year | | | Average Reported Summary Compensation Table Total for Non-PEO NEOs | | | Average Reported Value of Equity Awards | | | Average Equity Award Adjustments(a) | | | Average Compensation Actually Paid to Non-PEO NEOs | | ||||||||||||
2022 | | | | $ | 2,076,241 | | | | | $ | 1,169,181 | | | | | -$ | 728,127 | | | | | $ | 178,933 | | |
2021 | | | | $ | 2,161,897 | | | | | $ | 1,084,278 | | | | | $ | 1,960,997 | | | | | $ | 3,038,616 | | |
2020 | | | | $ | 1,730,387 | | | | | $ | 1,117,564 | | | | | $ | 721,591 | | | | | $ | 1,334,414 | | |
Year | | | Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year | | | Change in Fair Value of Equity Awards Granted in Prior Years that Remain Outstanding and Unvested as of Year End | | | Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year | | | Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year | | | Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year | | | Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation | | | Total Average Equity Award Adjustments | | |||||||||||||||||||||
2022 | | | | $ | 594,989 | | | | | -$ | 1,209,493 | | | | | | — | | | | | -$ | 113,622 | | | | | | — | | | | | | — | | | | | -$ | 728,127 | | |
2021 | | | | $ | 1,520,688 | | | | | $ | 380,546 | | | | | | — | | | | | $ | 59,764 | | | | | | — | | | | | | — | | | | | $ | 1,960,997 | | |
2020 | | | | $ | 1,354,604 | | | | | -$ | 437,983 | | | | | | — | | | | | -$ | 195,031 | | | | | | — | | | | | | — | | | | | $ | 721,591 | | |
| | The selection of qualified directors is critical to the long-term success of the Company and its shareholders. Director nominees must be able to contribute significantly to the Board’s discussion and decision-making on the broad array of complex issues facing the Company. The Board’s established process for director selection begins with an assessment of our strategic objectives and the skills, experience and qualifications needed to further those objectives. Through that process, the Board has determined that its nominees for election as directors at the The Board is unclassified. Directors are elected for one-year terms. You are being asked to vote, by separate ordinary resolutions, on the election of the following nine (9) director nominees, each for a one-year term: Francesco Bianchi Stacy William Kozy Daniel Moore Dr. Sharon O’Kane Andrea Saia Todd Schermerhorn Brooke Story Peter Wilver Detailed information about each director nominee’s background, skill sets and areas of expertise can be found beginning on page | | | | Vote Each director nominee is elected by a simple majority of the total votes cast. Election is by a majority of the votes cast in an uncontested election such as this one. In a contested election, directors are elected by a plurality of the votes case. Board Recommendation: FOR the election to the Board of each of the director | | |
| | Our shareholders are entitled to cast an advisory vote at the AGM to approve the compensation of our NEOs, as disclosed in this proxy statement. The shareholder vote is an advisory vote only and is not binding on us, the Board, or the Compensation Committee but is required by Section 14A of the Exchange Act. Although the vote is non-binding, the Compensation Committee and the Board value your opinions and will consider the outcome of the vote in establishing compensation philosophy and making future compensation decisions. As described more fully in the “Compensation Discussion and Analysis” and “Executive Compensation” sections of this proxy statement, our NEOs are compensated in a manner consistent with our business strategy, competitive practice, sound compensation governance principles and shareholder interests and concerns. Our compensation policies and decisions are focused on We are requesting your non-binding vote to approve the compensation of our NEOs as disclosed pursuant to Item 402 of Regulation S-K, and as described in the “Compensation Discussion and Analysis” and “Executive Compensation” sections of the proxy statement. | | | | Vote Required: This advisory vote will be approved if there is an affirmative vote of a simple majority of the total votes cast by members present at the AGM, in person or by proxy, and entitled to vote on the proposal. Board Recommendation: FOR the approval of the compensation of our NEOs as disclosed in this proxy statement, including the Compensation Discussion and Analysis, compensation tables, and narrative | | |
| | The Audit and Compliance Committee has appointed PwC-US as our independent registered public accounting firm for the year ending December 31, We anticipate that a representative of PwC-US or an affiliated member firm will be present at the AGM. The representative will be given the opportunity to make a statement if he or she desires to do so and is expected to be available to respond to any appropriate questions that may be submitted by shareholders at the AGM. | | | | Vote Required: This ordinary resolution vote will be approved if there is an affirmative vote of a simple majority of the total votes cast by members present at the AGM, in person or by proxy, and entitled to vote on the proposal. If this proposal does not receive the required vote for approval, the Audit and Compliance Committee will reconsider the appointment but may decide to maintain its appointment of PwC-US. Board and Audit and Compliance Committee Recommendation: FOR the ratification of the appointment of PwC-US as the Company’s independent registered public accounting firm for the year ending December 31, | | |
| | Year Ended December 31, 2020 | | Year Ended December 31, 2021 | | | Year Ended December 31, 2021 | | Year Ended December 31, 2022 | | ||||||||||||||||
Audit Fees(1) | | | $ | 6,270 | | | | $ | 4,650 | | | | | $ | 4,650 | | | | $ | 5,250 | | | ||||
Audit-Related Fees(2) | | | $ | 260 | | | | $ | 325 | | | | | $ | 325 | | | | $ | 35 | | | ||||
Tax Fees(3) | | | $ | 448 | | | | $ | 538 | | | | | $ | 538 | | | | $ | 299 | | | ||||
All Other Fees(4) | | | $ | 1 | | | | $ | 1 | | | | | $ | 1 | | | | $ | 1 | | | ||||
Total | | | $ | 6,979 | | | | $ | 5,514 | | | | | $ | 5,514 | | | | $ | 5,585 | | |
| | Proposal No. 4 is to approve the Amended and Restated LivaNova PLC 2022 Incentive Award Plan We are seeking shareholder approval of the The Company currently grants equity incentive awards to its employees under the LivaNova PLC 2022 Incentive Award Plan that was approved by our shareholders at our 2022 Annual General Meeting of Shareholders (the “Existing Plan”). Due to the recent decrease in the price of our Ordinary Shares, our rate of usage, or run rate, of shares under the Existing Plan has increased. As a result, we anticipate that in 2024 (before the 2024 AGM), the number of authorized shares remaining under the Existing Plan will be insufficient for the Company to make equity-based compensation a meaningful part of our employees’ and executives’ overall compensation. As of March 31, 2023, 925,796 shares remained available for future grants under the Existing Plan in the form of options or stock appreciation rights (“SARs”), and 488,850 shares remained available for future grants in the form of awards other than options or SARs. The Board approved and adopted the As of March 31, 2023, a total of 3,712,198 shares were subject to outstanding awards of options or SARs under the Existing Plan and other predecessor plans. These awards had a weighted | | | | Vote Required: This ordinary resolution will be approved if there is an affirmative vote of a simple majority of the total votes cast by members present at the AGM, in person or by proxy, and entitled to vote on the proposal. Board Recommendation: FOR the approval of the Amended and Restated LivaNova PLC 2022 Incentive Award Plan. | | |
| | average exercise price of $61.55 and a weighted average remaining contractual life of 7.42 years. In addition, 1,355,391 shares were subject to other types of awards outstanding under the Existing Plan If this proposal does not receive the required vote for approval, then the Existing Plan will remain in effect in accordance with its existing terms, and we will continue to grant equity incentive awards under the Existing Plan. However, as noted above, in 2024 (before the 2024 AGM) we expect that we may have an insufficient number of shares available to make equity-based compensation a meaningful part of our employees’ and executives’ overall compensation. Further, we believe our ability to retain and attract talented personnel could be adversely affected due to the ability of our competitors to offer long-term equity compensation to those individuals and our inability to do so. Without sufficient share capacity in our compensation program, we could lose employees or be forced to pay more compensation in cash to maintain competitive levels of compensation. |
| | | | | |
Name/Group | | | SARs | | | RSUs | | | PSUs(1) | | |||||||||
Damien McDonald, Former CEO | | | | | 81,613 | | | | | | 38,416 | | | | | | 76,832 | | |
Alex Shvartsburg, CFO | | | | | 20,089 | | | | | | 9,456 | | | | | | 18,912 | | |
Marco Dolci, President, Cardiopulmonary BU | | | | | 12,555 | | | | | | 5,910 | | | | | | 11,820 | | |
Keyna Skeffington, Senior Advisor and Former SVP and General Counsel | | | | | — | | | | | | — | | | | | | — | | |
Trui Hebbelinck, CHRO | | | | | 11,300 | | | | | | 5,319 | | | | | | 10,637 | | |
All executive officers as a group (5 persons) | | | | | 125,557 | | | | | | 59,101 | | | | | | 118,201 | | |
All non-executive directors as a group (9 persons) | | | | | — | | | | | | — | | | | | | — | | |
Each associate of the above-mentioned directors or executive officers | | | | | — | | | | | | — | | | | | | — | | |
Each other person who received or is to receive 5% of such options, warrants or rights | | | | | — | | | | | | — | | | | | | — | | |
All employees (other than executive officers) as a group (609 persons) | | | | | 848,647 | | | | | | 462,932 | | | | | | 70,916 | | |
| | The action requested in this Under the Companies Act, the directors may only allot shares in the Company or grant rights to subscribe for, or to convert any security, into shares in the Company if they are authorized to do so by the Company’s Articles of Association or by shareholder resolution. The requirement for such authorization to allot by the Company’s shareholders is an additional step not generally required when companies domiciled in the US are issuing securities. The directors believe that it is important for the Company to retain the flexibility to allot shares on an accelerated basis should the directors determine it is necessary or advisable and in the best interests of shareholders, without incurring the costs or delays associated with calling a special meeting and preparing and circulating proxy materials to approve specific allotments of shares. Therefore, the Company is now requesting that its Board have the authority to allot up to an aggregate nominal amount of | | | | Vote Required: This ordinary resolution will be approved if there is an affirmative vote of a simple majority of the total votes cast by members present at the AGM, in person or by proxy, and entitled to vote on the proposal. Board Recommendation: FOR the grant of authority to allot shares. | | |
| | granted, lapse at the end of the next annual general meeting of the Company or, if earlier, the close of business on the date that is fifteen (15) months after the date on which the resolution is passed, which is in line with the approach taken by public companies listed in the UK. The Company sought a similar authority at the AGMs held in 2022, 2021 and 2020, although the limit referred to above has been adjusted this year to reflect the latest Institutional Shareholders Services (ISS) guidelines. The directors have no present intention to exercise the authority sought under this resolution, other than to satisfy options and other awards to the non-employee directors of the Company who are not covered by the 2022 Plan The approval of this resolution by the Company’s shareholders will not substitute for any approvals that may be required for a specific transaction under any applicable Nasdaq listing rules. | | | | | | |
| | This action, like cash up to an aggregate nominal amount of it not be required to offer pre-emption rights to existing shareholders. The authority sought under this resolution will, if granted, lapse at the end of the next annual general meeting of the Company or, if earlier, the close of business on the date that is fifteen (15) months after the date on which the resolution is passed, which is in line with the approach taken by public companies listed in the UK. This resolution, if passed, would give the directors the power to allot new equity securities or to sell treasury shares held by the Company for cash without first offering them to shareholders in proportion to their existing holdings, subject to the limits set forth above. Under the Companies Act, when an allotment of shares is for cash, the Company must first offer those shares on the same terms to existing shareholders of the Company on a pro-rata basis (commonly referred to as statutory pre-emption rights) unless these statutory pre-emption rights are disapplied by approval of the shareholders. The requirement to first offer shares to existing shareholders is an additional step not generally required when companies domiciled in the United States are issuing securities. The directors believe that it is important for the Company to retain the flexibility to issue shares on an accelerated basis should the | | | | Vote Required: This special resolution will be approved if there is an affirmative vote of at least 75% of the total votes cast on the resolution by members present at the AGM, in person or by proxy, and entitled to vote on the proposal. Board Recommendation: FOR the proposal to disapply pre-emption rights. | | |
| | The Company sought a similar authority at the AGMs held in 2022, 2021 The directors have no present intention to exercise the authority sought under this resolution, other than to satisfy options and other awards to the non-employee directors of the Company who are not covered by the 2022 Plan The approval of this resolution by the Company’s shareholders will not substitute for any approvals that may be required for a specific transaction under any applicable Nasdaq listing rules. | | | | | | |
| | The Board considers that appropriate remuneration of directors plays a vital part in helping us to achieve our overall objectives, and accordingly, and in compliance with the Companies Act, we are providing shareholders with the opportunity to vote on an advisory resolution approving the directors’ remuneration report included in our UK Annual Report. This proposal is similar to Proposal 2 regarding the compensation of our NEOs. However, the directors’ remuneration report is concerned solely with the remuneration of our executive and non-executive directors and is required under the Companies Act. We encourage shareholders to read the directors’ remuneration report as set forth in the UK Annual Report and the directors’ remuneration policy approved by shareholders in The directors’ remuneration report for | | | | Vote Required: This advisory vote will be approved if there is an affirmative vote of a simple majority of the total votes cast by members present at the AGM, in person or by proxy, and entitled to vote on the proposal. This vote is advisory only, pursuant to the Companies Act, and the directors’ entitlement to receive remuneration is not conditional on it. Payments made or promised to directors will not have to be repaid, reduced or withheld in the event that the resolution is not passed. The resolution and vote are a means of providing shareholder feedback to the Board. The Compensation Committee will review and consider the outcome of the vote in connection with the ongoing review of our executive director and non-executive director compensation programs. Board Recommendation: FOR the approval of the | | |
| | The Board year ended December 31, 2022. In accordance with its obligations under English law, the | | | | Vote Required: This ordinary resolution will be approved if there is an affirmative vote of a simple majority of the total votes cast by members present at the AGM, in person or by proxy, and entitled to vote on the proposal. Board Recommendation: FOR |
| |
| | Under the Companies Act, the Company is required to appoint the UK statutory auditor at each meeting at which the UK Annual Report and accounts are presented to shareholders, to hold office until the conclusion of the next such meeting. PwC-UK has served as the Company’s UK statutory auditor since The Audit and Compliance Committee has recommended to the Board the re-appointment of PwC-UK as the Company’s UK statutory auditor and has confirmed to the Board that its recommendation is free from third party influence and that no restrictive contractual provisions have been imposed on the Company limiting the choice of auditor. | | | | Vote Required: This ordinary resolution will be approved if there is an affirmative vote of a simple majority of the total votes cast by members present at the AGM, in person or by proxy, and entitled to vote on the proposal. If this ordinary resolution is not approved, the Board may appoint an auditor to fill the vacancy. Board and Audit and Compliance Committee FOR the re-appointment of PwC-UK as the Company’s UK statutory auditor under the Companies Act to hold office from the conclusion of the meeting until the conclusion of the | | |
| | Under the Companies Act, the remuneration of our UK statutory auditor must be fixed in a general meeting or in such manner as may be determined in a general meeting. We are asking our shareholders to authorize the Board and/or the Audit and Compliance Committee of the Company to determine the remuneration of PwC-UK in its capacity as the Company’s UK statutory auditor under the Companies Act. | | | | Vote Required: This ordinary resolution will be approved if there is an affirmative vote of a simple majority of the total votes cast by members present at the AGM, in person or by proxy, and entitled to vote on the proposal. Board Recommendation: FOR the authorization of the Board and/or the Audit and Compliance Committee to determine the Company’s UK statutory auditor’s remuneration. | | |
Name of Beneficial Owner | | | Amount and Nature of Beneficial Ownership(1) | | |||||||||||||||||||||
| Shares Owned | | | Shares Acquirable Within 60 Days | | | Total Beneficial Ownership | | | Percent of Class(2) | | ||||||||||||||
Named Executive Officers: | | | | | | | | | | | | | | | | | | | | | | | | | |
Damien McDonald | | | | | 85,969 | | | | | | — | | | | | | 85,969 | | | | | | * | | |
Marco Dolci | | | | | 2,289 | | | | | | — | | | | | | 2,289 | | | | | | * | | |
Trui Hebbelinck | | | | | 3,001 | | | | | | — | | | | | | 3,001 | | | | | | * | | |
Alex Shvartsburg | | | | | 5,425 | | | | | | — | | | | | | 5,425 | | | | | | * | | |
Keyna Skeffington | | | | | 7,903 | | | | | | — | | | | | | 7,903 | | | | | | * | | |
Directors: | | | | | | | | | | | | | | | | | | | | | | | | | |
Francesco Bianchi | | | | | 5,292 | | | | | | 1,346 | | | | | | 6,638 | | | | | | * | | |
Stacy Enxing Seng | | | | | 3,796 | | | | | | 1,346 | | | | | | 5,142 | | | | | | * | | |
William Kozy | | | | | 6,320 | | | | | | 2,264 | | | | | | 8,584 | | | | | | * | | |
Daniel Moore | | | | | 24,630 | | | | | | 1,346 | | | | | | 25,976 | | | | | | * | | |
Alfred Novak | | | | | 11,368 | | | | | | 1,346 | | | | | | 12,714 | | | | | | * | | |
Dr. Sharon O’Kane | | | | | 6,261 | | | | | | 1,346 | | | | | | 7,607 | | | | | | * | | |
Dr. Arthur L. Rosenthal | | | | | 22,383 | | | | | | 1,346 | | | | | | 23,729 | | | | | | * | | |
Andrea Saia | | | | | 6,775 | | | | | | 1,346 | | | | | | 8,121 | | | | | | * | | |
Todd Schermerhorn | | | | | 1,024 | | | | | | 1,346 | | | | | | 2,370 | | | | | | * | | |
Peter Wilver | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | |
All current executive officers and directors as a group (14 persons) | | | | | 192,436 | | | | | | 13,032 | | | | | | 205,468 | | | | | | * | | |
5% Holders:(3) | | | | | | | | | | | | | | | | | | | | | | | | | |
BlackRock, Inc.(4) | | | | | 6,349,305 | | | | | | — | | | | | | 6,349,305 | | | | | | 11.88 | | |
155 East 52nd Street | | | | | | | | | | | | | | | | | | | | | | | | | |
New York, NY 10055 | | | | | | | | | | | | | | | | | | | | | | | | | |
PRIMECAP Management Company(5) | | | | | 4,415,445 | | | | | | — | | | | | | 4,415,445 | | | | | | 8.26 | | |
177 E. Colorado Blvd., 11th Floor | | | | | | | | | | | | | | | | | | | | | | | | | |
Pasadena, CA 91105 | | | | | | | | | | | | | | | | | | | | | | | | | |
Harris Associates L.P.(6) | | | | | 3,823,266 | | | | | | — | | | | | | 3,823,266 | | | | | | 7.15 | | |
111. S. Wacker, Suite 4600 | | | | | | | | | | | | | | | | | | | | | | | | | |
Chicago, IL 60606 | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | Amount and Nature of Beneficial Ownership(1) | | |||||||||||||||
Name of Beneficial Owner | | | Shares Owned | | | Shares Acquirable Within 60 Days | | | Total Beneficial Ownership | | | Percent of Class(2) | | ||||||||||||
Named Executive Officers: | | | | | | | | | | | | | | | | | | | | | | | | | |
Damien McDonald | | | | | 111,847 | | | | | | — | | | | | | 111,847 | | | | | | * | | |
Marco Dolci | | | | | 7,708 | | | | | | — | | | | | | 7,708 | | | | | | * | | |
Trui Hebbelinck | | | | | 7,308 | | | | | | — | | | | | | 7,308 | | | | | | * | | |
Alex Shvartsburg | | | | | 8,100 | | | | | | — | | | | | | 8,100 | | | | | | * | | |
Keyna Skeffington | | | | | 13,163 | | | | | | — | | | | | | 13,163 | | | | | | * | | |
Directors: | | | | | | | | | | | | | | | | | | | | | | | | | |
Francesco Bianchi | | | | | 6,540 | | | | | | 2,082 | | | | | | 8,622 | | | | | | * | | |
Stacy Enxing Seng | | | | | 5,013 | | | | | | 2,082 | | | | | | 7,095 | | | | | | * | | |
William Kozy | | | | | 8,470 | | | | | | 3,284 | | | | | | 11,754 | | | | | | * | | |
Daniel Moore | | | | | 25,896 | | | | | | 2,082 | | | | | | 27,978 | | | | | | * | | |
Dr. Sharon O’Kane | | | | | 6,971 | | | | | | 2,082 | | | | | | 9,053 | | | | | | * | | |
Andrea Saia | | | | | 8,008 | | | | | | 2,082 | | | | | | 10,090 | | | | | | * | | |
Todd Schermerhorn | | | | | 2,334 | | | | | | 2,082 | | | | | | 4,416 | | | | | | * | | |
Peter Wilver | | | | | — | | | | | | 2,082 | | | | | | 2,082 | | | | | | * | | |
Brooke Story | | | | | — | | | | | | — | | | | | | — | | | | | | * | | |
All current executive officers and directors as a group (14 persons) | | | | | 86,348 | | | | | | 17,858 | | | | | | 104,206 | | | | | | * | | |
5% Holders:(3) | | | | | | | | | | | | | | | | | | | | | | | | | |
BlackRock, Inc.(4) | | | | | 6,834,335 | | | | | | — | | | | | | 6,834,335 | | | | | | 12.69 | | |
155 East 52nd Street | | | | | | | | | | | | | | | | | | | | | | | | | |
New York, NY 10055 | | | | | | | | | | | | | | | | | | | | | | | | | |
PRIMECAP Management Company(5) | | | | | 4,594,917 | | | | | | — | | | | | | 4,594,917 | | | | | | 8.53 | | |
177 E. Colorado Blvd., 11th Floor | | | | | | | | | | | | | | | | | | | | | | | | | |
Pasadena, CA 91105 | | | | | | | | | | | | | | | | | | | | | | | | | |
Plan category | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (#) | | | Weighted-average exercise price of outstanding options, warrants and rights ($) | | | Number of securities remaining available for future issuance under equity compensation plans (#) | | |||||||||
Equity compensation plans approved by security holders | | | | | | | | | | | | | | | | | | | |
LivaNova PLC 2015 Incentive Award Plan and Sub-Plan(1) | | | | | 3,872,420 | | | | | | 63.98 | | | | | | 3,575,752 | | |
Cyberonics Legacy Plans(2) | | | | | 219,807 | | | | | | 53.33 | | | | | | 1,858,706 | | |
Equity compensation plans not approved by security holders | | | | | | | | | | | | | | | | | | | |
Cyberonics, Inc. New Employee Equity Inducement Plan(3) | | | | | | | | | | | | | | | | | 290,185 | | |
Total | | | | | 4,092,227 | | | | | | 58.65 | | | | | | 5,724,643 | | |
Plan category | | | Number of securities to be issued upon exercise of outstanding options, warrants and rights (#) | | | Weighted- average exercise price of outstanding options, warrants and rights ($) | | | Number of securities remaining available for future issuance under equity compensation plans (#) | | |||||||||
Equity compensation plans approved by security holders | | | | | | | | | | | | | | | | | | | |
LivaNova PLC 2022 Incentive Award Plan and Sub-plan(1) | | | | | 62,215 | | | | | | — | | | | | | 3,037,785 | | |
LivaNova PLC 2015 Incentive Award Plan and Sub-Plan(2) | | | | | 3,706,379 | | | | | | 69.19 | | | | | | 30,417 | | |
Cyberonics Legacy Plans(3) | | | | | 219,807 | | | | | | 53.33 | | | | | | — | | |
Total | | | | | 3,917,729 | | | | | | 68.44 | | | | | | 3,354,985 | | |